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Für Elsa, Freya und Selma 
 
 
 
 
 
 
 
 
 
 
 
there’s a whale in the moon when it’s clear 
  
  
 
 
 
  
  
 
 
Sein Blick ist vom Vorübergehn der Stäbe 
so müd geworden, dass er nichts mehr hält. 
Ihm ist, als ob es tausend Stäbe gäbe 
und hinter tausend Stäben keine Welt. 
Der weiche Gang geschmeidig starker Schritte, 
der sich im allerkleinsten Kreise dreht, 
ist wie ein Tanz von Kraft um eine Mitte, 
in der betäubt ein großer Wille steht. 
 
Nur manchmal schiebt der Vorhang der Pupille 
sich lautlos auf –. Dann geht ein Bild hinein, 
geht durch der Glieder angespannte Stille – 
und hört im Herzen auf zu sein. 
 
Rainer Maria Rilke  
 SAMMANFATTNING PÅ SVENSKA 
Immunförsvaret har inte bara till uppgift att skydda mot infektioner utan har också visats vara 
viktigt för normala hjärnfunktioner och verkar dessutom vara en del i uppkomsten av sjukdomar 
som rör mentala funktioner. Immunsignalering i centrala nervsystemet spelar en stor roll vid 
anläggning och utveckling av hjärnan via samspel med bland annat neurotransmittorer, 
neuroendokrina hormoner, cytokiner och deras respektive receptorer. Att utforska samspelet 
mellan hjärna, immunförsvar och beteende kan bidra till ökad insikt kring orsaker till 
uppkomsten av psykiska sjukdomar, samt ge uppslag till behandling av dessa. 
Syftet med denna avhandling var att undersöka immunförsvarets roll i dels en djurmodell som 
används för studier av depression och dels i två kliniska studier rörande autismliknande 
personlighetsdrag samt bipolär sjukdom. 
I djurförsöken användes råttor av typen Flinders sensitive line (FSL), som utgör en genetisk modell 
där djuren uppvisar ett depressionsliknande beteende. Avsikten var att studera uttrycket av gener 
i hjärnan med betydelse för immunsystemet efter aktivering av kroppens immunförsvar (Artikel I) 
och efter behandling med ett antidepressivt läkemedel (Artikel II). Några av dessa gener uttrycktes 
i en lägre grad hos råttorna jämfört med vanliga kontrolldjur, ett fynd som vi sedan kunde upprepa 
i nya försök. Aktivering av immunförsvaret gav också upphov till förändringar i uttrycket av vissa 
immunrelaterade gener i hjärnan. Även antidepressiv behandling med läkemedlet escitalopram 
förändrade uttrycket av vissa gener, i synnerhet S100B och serotoninreceptor 2A, i hjärndelarna 
amygdala och hypothalamus som anses vara av betydelse för depression. Denna djurmodell tycks 
således vara användbar för att studera mekanismer som sammanlänkar immunsystemet med 
depressionsliknande beteende samt effekten av antidepressiv behandling.   
I de kliniska studierna i detta arbete studerade vi huruvida varianter i immunförsvarsrelaterade 
gener är associerade med psykiatriska tillstånd och volym av olika hjärndelar. Exempelvis såg vi att 
variationer i genen som kodar för NF-kB inhibitor-like protein 1 (NFKBIL1) var associerade med 
autism-liknande personlighetsdrag och språksvårigheter (Artikel III). Vidare undersökte vi 
sambandet mellan varianter av genen som kodar för cytokinen interleukin 1beta (IL-1beta) och 
volym av olika hjärnregioner hos patienter med bipolär sjukdom och friska kontroller (Artikel IV). 
Vi fann här ingen genetisk skillnad mellan patienter och kontroller. Däremot påvisades ett 
samband mellan genvariant och volym av putamen i vänstra hjärnhalvan hos både patienter och 
kontroller, vilket kan tolkas som att IL-1beta är inblandad i utveckling av nervsystemet. 
Sammanfattningsvis redovisas i denna avhandling samband mellan komponenter i 
immunförsvaret och psykiatriska tillstånd samt förändrad utveckling av nervsystemet, vilket 
ytterligare understryker immunförsvarets roll för mentala funktioner. 
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ABSTRACT 
The immune system has been implicated in the mechanisms underlying many psychiatric disorders. 
Immune mediators are expressed in the central nervous system (CNS) not only in response to harmful 
stimuli, but also in a constitutive manner, and serve as important plasticity factors during development. 
There is complex bidirectional communication between the immune system and the CNS throughout 
life which is based on interactions between neurotransmitters, neuroendocrine hormones, cytokines, and 
their respective receptors. Exploring the interplay between brain, behaviour and immunity is central to 
our understanding of the pathology of psychiatric morbidity. 
The aim of this thesis is to investigate the role of some aspects of the immune system in several psychiatric 
conditions, both in experimental and clinical contexts. 
We used the Flinders sensitive line (FSL), a genetic animal model of depression, to study central gene 
expression of markers related to immune response and neurotransmission following immune stimulation 
and antidepressant treatment. Several genes were found to be expressed differently in rats displaying 
depressive-like behaviour compared to their controls (Paper I), a finding that we replicated in Paper II. 
Additionally, we showed that antidepressant treatment with escitalopram altered expression of several 
genes, notably the astrocyte-derived protein S100B, and the serotonin receptor 5-HT2A, in the amygdala 
and hypothalamus (Paper II), two brain regions that have been shown to be of relevance for the effect of 
antidepressant treatment. Our results support the use of the FSL model for studying the role of these 
immune-related markers in depression and antidepressant treatment. 
In the clinical studies included in this thesis, we found that genetic variants in immune-related genes were 
associated with neuropsychiatric traits and the volume of certain brain regions. The gene encoding the 
NF-kB inhibitor-like protein 1 (NFKBIL1) was found to be associated with autistic-like traits, as well as 
with language impairment in a cohort from the general population (Paper III). We further investigated 
the effect of genetic variation in the gene coding for interleukin-1beta (IL1B) on the volume of several 
brain regions in a case-control population of patients diagnosed with bipolar disorder (Paper IV). 
Genotype distribution did not differ between patients and controls, suggesting that variants in IL1B may 
not be associated with bipolar disorder. However, we found associations between IL1B polymorphisms 
and the volume of the putamen in the left hemisphere in patients and controls, suggesting that genetic 
variation in IL1B may influence neurodevelopment. 
In conclusion, this thesis demonstrates associations between immune mediators and mental functions, 
as well as altered brain development in humans. Also, insight is gained into the use of the FSL animal 
model for investigating the impact of the immune system for depression. Taken together, our findings 
confirm the importance of the immune system for the development of psychiatric disorders. 
Keywords: immune system, mental disorders, polymorphisms, depression, autism, bipolar disorder, 
SSRI, S100B, 5-HTR2A, Flinders sensitive line 
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INTRODUCTION 
The distinction between mind and body, and thus between mental and physical 
health, is a philosophical question that humans have contemplated for 
thousands of years. The father of modern medicine, Hippocrates, developed the 
theory of the four humors – blood, yellow bile, black bile, and phlegm – 
hypothesizing that the relative proportions of these substances regulate human 
temperament and behaviour, and that their correct balance defines “health”. 
However, more than 2000 years later the neurobiology of emotions and 
behaviour is far from understood, and there are still many who disregard that 
disorders of thought, behaviour, or mood have a biological explanation. 
One of the first successful pharmacological treatments was of an illness that was 
then believed to be purely psychiatric, i.e., the treatment of paralytic dementia, 
also known as general paralysis of the insane. The progressive course of the disease 
went from symptoms of mania and euphoria to seizures, cognitive decline and 
dementia, ultimately leading to paralysis and death, and it affected more than a 
tenth of all institutionalized psychiatric patients at the turn of the last century 1. 
It was later found to be due to chronic meningoencephalitis caused by infection 
with the bacterium Treponema pallidum, also known as syphilis, and successfully 
treated by the antibiotic penicillin. The increasing knowledge about etiology and 
pathophysiology of mental disorders will hopefully continue to give rise to 
preventive strategies and better treatment, and help to relieve us further from 
the burden they impose. 
Our behaviour is determinded by (i) our genes, which form the basis for our 
mental functions, and (ii) the environment we are exposed to, which determines 
how that basis is used. Not even identical twins, which have the exact same 
genotype, think and behave entirely alike, due to differences during embryonic 
and adult environments. The immune system plays a pivotal role during 
neurodevelopment and can affect it on several levels; differences in the 
deoxyribonucleic acid (DNA) coding for immune-related genes, as well as pre- 
and postnatal immune activation have the ability to alter the structure and 
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function of the brain and subsequently cause changes in the way we think and 
feel 2. 
THE IMMUNE SYSTEM 
Our immune system defends us against a wide variety of harmful organisms, 
such as pathogenic bacteria, viruses and parasites, and in order to do so, it has 
to distinguish between foreign material and our own healthy tissue. An 
imbalance of the immune system can lead to disorders such as 
immunodeficiencies, where the immune system is less active than normal and 
thus leaves us susceptible to life-threatening infections; autoimmunity, where an 
overactive immune system attacks healthy tissues; and inflammatory diseases. 
The immune system consists of two components in which different cells and 
molecules work cooperatively to provide host defense and to restore 
homeostasis. These two components are the innate and the adaptive immune 
responses. 
Innate and adaptive immune responses 
The first line of defense against pathogens is provided by the evolutionarily older 
innate immune response. It consists of physical and chemical barriers, including 
skin, mucosa, antimicrobial molecules (blood proteins such as complement 
components), and cellular defense mediated through phagocytes (macrophages 
and neutrophils) and natural killer cells. It specifically targets molecules shared 
by pathogens such as the bacterial carbohydrate lipopolysaccharide (LPS), and 
molecules released by damaged host cells. Its diversity is limited, as it is germline 
encoded and not able to “learn”, but it is highly important for the organism, as 
it is the only immediate protection against pathogens and tissue injury before 
the adaptive immune response is activated. 
The adaptive immune system evolved in early vertebrates and is antigen-specific. 
It requires recognition of specific “non-self” antigens during a process called 
antigen presentation. There are two types of adaptive immune responses, called 
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humoral immunity and cell-mediated immunity, which differ in their 
components and eliminate different types of microbes. Humoral immunity is 
mediated by antibodies that are produced by B-lymphocytes and is the principle 
defense mechanism against extracellular microbes and their toxins. The antigen 
binding fragments of antibodies have a large diversity as they are produced by 
somatic recombination of their gene segments. Furthermore, the adaptive 
immune response has a memory function, and is able to remember if it had been 
presented to a specific antigen before, and if so, can augment the reaction. Cell-
mediated immunity is mediated by T-lymphocytes and targets intracellular 
microbes such as viruses and some bacteria that are inaccessible to circulating 
antibodies. 
Inflammation 
Inflammation is an essential response to harmful stimuli such as infection and 
tissue damage, and is part of the innate immune response. It can be classified as 
either acute or chronic.  
The cardinal symptoms of acute inflammation are rubor (redness), calor (heat), 
tumor (swelling), dolor (pain), and functio laesa (loss of function). Immune 
molecules and cells (predominantly neutrophils) are recruited to sites of 
infection or tissue damage in order to eliminate the cause of the inflammatory 
reaction, and an inflammatory cascade is initiated via the secretion of mediators 
including cytokines, chemokines, histamines, and complement factors. 
Neutrophils are activated and start attacking the pathogen by releasing toxic 
effector molecules. However, these do not distinguish between pathogen and 
healthy host tissue, which gets damaged in the process. After elimination of the 
pathogen, further immune cells such as macrophages are recruited to remove 
cell debris and restore the tissue at the site of inflammation. For restoration to 
happen, an important switch in secretion from pro-inflammatory mediators to 
anti-inflammatory ones must take place. Instead of neutrophils, monocytes are 
then recruited to the tissue, which facilitate the removal of dead cells and initiate 
tissue remodeling. 
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While acute inflammation is vital to our survival, leading to destruction of 
invading pathogens and initiating cell recovery, prolonged inflammation known 
as chronic inflammation does not seem to serve a protective function. It is 
characterized by simultaneous inflammation and repair, and does not appear to 
be caused by the classic instigators of inflammation—infection and injury—but 
instead by a homeostatic imbalance that is not directly related to fighting 
infection or tissue repair. This can happen when the acute inflammatory 
response was not strong enough and fails to eliminate the irritant, when the 
persistent irritant is not large enough to elicit an acute inflammatory response, 
or by autoimmune reactions 3. The symptoms are much less severe than during 
acute inflammation but can still cause harm. Chronic inflammation has been 
recognized as being involved in a wide variety of diseases including 
cardiovascular diseases 4, diabetes 5 and neurodegenerative diseases 6. 
Furthermore, mounting evidence is pointing to a role of inflammation in e.g. 
neuropsychiatric disorders, as will be discussed in more detail later. 
Cytokines 
Cytokines are a vast and heterogenous group of small proteins that are secreted 
by a wide range of immune and non-immune cells. They are of importance in 
the transmission of information between the immune system, the endocrine 
system, and the nervous system, and they are involved in both innate and 
adaptive immune responses via autocrine signaling (binding to receptors on the 
same cell as part of autoregulatory mechanisms), paracrine signaling (binding to 
and inducing changes in nearby cells) and endocrine signaling (being secreted to 
the circulatory system and affecting distant target cells). Cytokines regulate 
various biological processes and include chemokines, interferons, interleukins 
(ILs), lymphokines, and tumor necrosis factors (TNFs), that are generally 
grouped into pro- or anti-inflammatory cytokines. Pro-inflammatory cytokines 
(e.g. IL-1b, IL-6 and TNF) augment inflammatory responses, while anti-
inflammatory cytokines (e.g. IL-4) dampen inflammation, and together they 
orchestrate initiation, maintenance, and termination of inflammation. 
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Cytokines are not stored in the cells that secrete them but their synthesis is 
initiated in response to an external signal, e.g. binding of a ligand to a cell surface 
receptor that leads to a signaling cascade resulting in the nuclear translocation 
of transcription factors such as nuclear factor kappa-B (NF-κB), which in turn 
activates expression of a plethora of inflammatory mediators. Newly transcribed 
messenger ribonucleic acid (mRNA) of cytokines is often unstable or rapidly 
degraded, and may require transcriptional or translational processing, like 
proteolytic cleavage of an inactive precursor molecule into an active product. 
This shows that cytokine expression is a highly regulated and transient process, 
but once synthesized, they are rapidly secreted, resulting in a burst of release 
when needed.  
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NEUROIMMUNOLOGY 
The central nervous system (CNS) has traditionally been viewed as an “immune-
privileged” area due to the existence of the blood brain barrier (BBB). The BBB 
was believed to make the CNS inaccessible to the immune system, with the 
exception occurring only during disease states, and the two systems were thought 
to be functionally independent of each other. This notion has been successfully 
challenged over the last decades. Advances in the field of neuroimmunology 
have shown that there is a complex bidirectional communication between the 
CNS and the immune system via multiple neuro-immune pathways, and 
although the immune-privilege does exist, it is relative. 
The blood-brain barrier 
The BBB is a complex structure which is built up of several components.  The 
predominant barrier is the vascular barrier, which is composed of endothelial 
cells, forming elaborate tight junctions and preventing diffusion. Some 
molecules can be carried from the blood through the endothelium into the 
cerebrospinal fluid (CSF) via e.g., transport molecules or vesicular transport. The 
basement membrane forms the second barrier. Its charged pores function as a 
molecular sieve, either repelling or binding charged molecules. Astrocytes form 
a layer around the basement membrane and maintain a constant ion-
concentration of the extracellular matrix, which is crucial for the electrical 
activity of neurons and their axons. Furthermore, perivascular macrophages and 
microglia cells patrol the area surrounding the BBB. If foreign material manages 
to pass through into the brain, it is taken up and degraded by them. 
Neuro-immune pathways 
The notion that the immune system and the CNS function in close association 
with each other was proposed decades ago by Besedovsky and Sorkin 7, but the 
molecular pathways underlying the intricate communication between the two 
systems took longer to elucidate. 
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There are several pathways in which the immune system can relay signals to the 
brain (Figure 1). The first one to be discovered was the humoral pathway; although 
cytokines are too large to pass the BBB freely, there are several proposed ways 
how they may affect the brain. Slowly diffusing cytokines, including IL-1beta, 
may pass through leaky regions of the BBB such as the choroid plexus and the 
circumventricular organs (CVOs) 8. Brain endothelial cells and perivascular 
macrophages that line the cerebral vasculature may produce cytokines and other 
inflammatory mediators such as prostaglandins and nitric oxide (NO) in 
response to circulating cytokines or pathogen-associated molecular patterns, and 
then release them into the brain parenchyma 9. Cytokines and even cells from 
the periphery can also enter directly into the CNS; cytokines may do so via active 
transport through saturable transport molecules 10, and activated microglia may 
recruit peripheral monocytes to the brain via production of monocyte 
chemoattractants 11, also referred to as the cellular pathway. In the neural pathway, 
the peripheral immune signal may be relayed to the brain by afferent nerves, e.g. 
the vagus nerve. These nerves express cytokine receptors which peripheral 
cytokines such as IL-1, IL-6 and TNF bind to, and the afferent nerves 
communicate the cytokine signals to relevant brain regions such as the 
hypothalamus and the amygdala 8,12. Once cytokine signals reach the CNS, there 
is a vast network of cells that express cytokines and their receptors, including 
microglia, astrocytes and neurons 9. These cells can cause a cytokine cascade 
within the CNS and may affect sleep, temperature regulation, food intake, 
cognition, and behaviour through alterations in neurotransmitter metabolism, 
neuroendocine function, and neural plasticity. 
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Figure 1. Representation of communication pathways from the peripheral immune system to the brain. 
Diffusing cytokines released from activated monocytes and macrophages access the brain at leaky regions of 
the BBB such as the circumventricular organs (CVOs), where they stimulate endothelial cells to release 
second messengers, e.g., more cytokines, prostaglandins, or nitric oxide (NO) into the brain parenchyma, 
called the humoral pathway (green). In the cellular pathway (pink) pro-inflammatory cytokines activate 
microglia to produce chemoattractants, which in turn recruit monocytes from the periphery into the brain. 
Cytokines can also bind to cytokine receptors on afferent nerve fibers in the vagus nerve, which relay the 
information to other neural pathways (blue). 
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There is also brain-to-immune signaling, where the nervous system regulates the 
immune system. It can do so through neuroendocrine peptide hormones, 
activation of the sympathetic nerves innervating lymphoid organs, or activation 
of the hypothalamic-pituitary-adrenal (HPA) axis, resulting in the release of anti-
inflammatory glucocorticoids 9, and all of these can have widespread effects on 
the immune system. A mechanism known as the inflammatory reflex, proposed 
and revised by Tracey et al. 13, states that the CNS reflexively regulates the 
inflammatory response, just as it controls other vital functions such as heart rate. 
Pro-inflammatory cytokines released by activated innate immune cells (e.g. 
macrophages) stimulate afferent vagus fibers, which leads to activation of the 
parasympathetic brainstem regions and the subsequent signaling in efferent 
vagus fibers in a reflex-like manner. This in turn activates the (sympathetic) 
splenic nerves, which results in recruitment of acetylcholine-producing T-cells 
that downregulate inflammation by interacting with cholinergic receptors on 
macrophages, causing inhibition of cytokine production 14. 
Immune mediators in the brain 
Cells in the CNS can be divided into neuronal cells and non-neuronal cells, 
called glia. Glia cells are responsible for homeostasis, myelination, support and 
protection for neurons, and include microglia, ependymal cells, and the 
macroglial cells oligodendrocytes and astrocytes. Below, two cell types relevant 
for this thesis are highlighted. 
Astrocytes 
Astrocytes are large star-shaped cells that are structurally and functionally 
associated with neurons and the cerebral microvasculature. They are derived 
from progenitor cells in the neuroepithelium of the developing CNS, and the 
genetic mechanisms of astrocytic cell differentiation are similar to those of 
neurons 15. Although they are unable to generate action-potentials, they can 
propagate intercellular Ca2+ waves over long distances in response to 
stimulation, and, similar to neurons, release transmitters in a Ca2+ dependent 
manner. Amongst the glial transmitters that are released by astrocytes are e.g. 
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classical transmitters (e.g. glutamate), chemokines, cytokines (e.g. TNF), 
peptides, and the Ca2+ binding protein S100B 16. Apart from their important 
roles in the maintenance of neural circuits, astrocytes are also modulators of 
synaptic transmission, and astrocyte dysfunction has been implicated in 
neurodevelopmental disorders such as autism 17. 
Microglia 
Microglia are the resident macrophages of the CNS. These immunocompetent 
cells are derived from yolk sac primitive macrophages during early development, 
and persist by self-renewal in the CNS. Microglia can be in a ramified “resting 
state” and an amoeboid “active state”. Depending on the type and duration of 
the activating stimulus, microglia can transform into different phenotypes, 
including pro-inflammatory (M1) and anti-inflammatory (M2) states 18. Upon 
activation, they proliferate and migrate to the site of injury, where they can 
destroy invading pathogens, remove debris, and promote tissue repair by 
secreting growth factors, and thus protect the CNS from potentially fatal damage 
and restore tissue integrity.  
In the resting state, however, microglia are far from inactive. They are constantly 
surveying their surrounding microenvironment for pathogens with their highly 
branched processes, and their function is modulated by neuronal activity and 
astrocytes 19. They are required for the formation of mature synapses during 
embryogenesis 20 and regulate adult neurogenesis 21. Microglia have been shown 
to play an important role in the activity-dependent elimination or pruning of 
inactive synapses, and thereby the formation of mature neural circuits. They 
make use of several signaling mechanisms, including chemokines and 
chemotaxis 20, as well as the classic complement cascade that is part of the innate 
immune system 22. Complement proteins such as complement component 3 
(C3) bind to immature synapses, being an important part of the developmental 
pruning of nonfunctional synapses. During the period of synaptic elimination 
microglia upregulate the expression of receptors that bind to these complement 
proteins, leading to engulfment and elimination of inactive synapses. Disruption 
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of the microglia-specific C3 signaling results in reduced microglia phagocytic 
function and sustained deficits in synaptic connectivity 22. 
Microglia and associated cytokines have received a great deal of attention in 
research regarding depression 23 and have been suggested as a promising target 
for depression treatment strategies 24. Increased microglial density has been 
found in several brain regions of suicide victims diagnosed with depression, 
bipolar disorder, and schizophrenia 25. Also, enhanced microglia activation 
during a major depressive episode has been reported in a positron emission 
tomography study 26. Microglia have been implicated as a link between maternal 
immune activation and disturbed fetal neurodevelopment 27. Nevertheless, their 
exact role in the pathophysiology of psychiatric disorders remains unknown. 
Brain development 
The development of the CNS is a complex series of dynamic and plastic 
processes. These are under highly constrained genetic regulation in a constantly 
changing environment. Development of the CNS begins in the third week after 
conception with the differentiation of neural progenitor cells and extends 
beyond adolescence 28. Both genetic factors and environmental input are 
fundamental for normal brain development, and disruption of either can alter 
neural outcomes to great extent. 
By the end of the embryonic period (i.e. nine weeks after conception) the 
fundamental structures of the brain have been formed. These will later become 
the cerebral hemispheres, diencephalon, cerebellum and brain stem. During 
fetal development (i.e. week 9 until birth) there is rapid growth and 
specialization of both cortical and subcortical structures, and the rudiments of 
the major fiber pathways are formed 29. Neurons are produced from six weeks 
after conception to midgestation, and immediately migrate to different brain 
areas where they begin to make connections with other neurons, establishing 
basic neural networks. Brain development continues after birth, with the brain 
increasing its size rapidly. Structural as well as functional changes in both grey 
matter (e.g. cell bodies and glia cells) and white matter (i.e. axons with myelin 
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sheaths) continue throughout childhood and adolescence and are reflected by 
changes in e.g. cognition and behaviour. 
Healthy brain development does not exclusively mean proliferation and growth; 
there are two important processes that are essential for CNS development that 
involve substantial loss of neural elements; naturally occurring cell death in 
neural populations, and massive overproduction of synaptic connections 
followed by the systemic elimination of up to 50% of these connections. While 
neuronal cell death occurs mostly prenatally, natural cell death of glia 
populations, as well as proliferation followed by pruning of synapses are largely 
postnatal events 28. There are far more connections during the early postnatal 
period compared to the adult brain, and this excessive connectivity is carefully 
pruned back via competitive processes that are influenced by an individual’s 
genetic make-up, as well as their environment and experiences. This also means 
that the developing brain is highly sensitive to both endogenous and exogenous 
signals. Experiences during the pre- and postnatal period, including nutrition, 
trauma, stress and infection, have been strongly connected to alterations in 
neural circuits and associated behavioural outcomes 30–33. 
Many components of the immune system have been found to play important 
roles during CNS development 34, including cytokines, complement factors, and 
members of the major histocompatibility complex class I (MHCI) and their 
receptors. This is not surprising, as accumulating evidence indicates a 
pleiotropic nature of proteins, that is to say that the same protein can have 
multiple, and paradoxically unrelated functions, within and between systems 34. 
Many proteins first discovered as a part of the immune system have now been 
discovered in the healthy CNS where they have non-immune functions. Hence, 
a vast molecular repertoire seems to be shared by the nervous and the immune 
systems 35. 
Although little is known about the exact role of immune mediators in brain 
development as of yet, animal studies have uncovered several examples 
supporting varied roles for these proteins, with microglia playing an important 
part; differentiation of progenitor cells into neurons and glia is dependent upon 
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local factors and intrinsic signals, such as IL-1, which is produced by developing 
microglia 36. During further development, microglia produce cytokines 
(including IL-1beta and TNF) which are important for ongoing neurogenesis 
within the developing brain, as well as chemokines that guide axons of new 
neurons via chemoattraction toward their new synaptic targets 37. TNF and 
MHC class I molecules have been suggested to be important for the 
strengthening of new synaptic connections within the brain 38,39. Finally, in the 
later stages of neurodevelopment, abundant or inappropriate synaptic 
connections are eliminated (synaptic pruning) and phagocytosed by microglia, 
as immune proteins such as C3 tag synapses for elimination during this 
process40. 
Neural plasticity 
Neural plasticity is the ability of the nervous system to change throughout an 
individual’s life, i.e. to modify itself, functionally and structurally, in response 
to changing environment, aging, or pathological insult. It is a key component of 
development and normal functioning of the brain, and responsive to experience 
and insult. In addition, it is necessary not only for neural networks to acquire 
new functional properties, but also for them to remain robust and stable. 
Nearly all neurological and psychiatric disorders have been associated with 
changes in neural plasticity, including reductions of adult hippocampal 
neurogenesis, diminished cortical dendritic arbors, deficits in long-term 
potentiation (LTP) and impaired synaptogenesis 41. Disruptions in neural 
plasticity have also been shown in depression, and modulation of neuronal 
adaptation has been implicated in the  treatment actions of antidepressants 42. 
The immune system plays a central role in various mechanisms underlying 
neural plasticity, both by communication pathways from the peripheral immune 
system to the brain and by signals produced by immune-competent cells within 
the CNS, involving neuro–glial communication 19. 
Under normal conditions, immune mechanisms positively regulate neural 
plasticity and neurogenesis, promoting learning, memory, and hippocampal 
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LTP. These beneficial effects of the immune system are mediated by interactions 
between the cellular and the non-cellular components. The cellular components 
include microglia, astrocytes, neurons, and peripheral immune cells such as T 
cells and macrophages 19. Their interplay involves the responsiveness of non-
neuronal cells to classical neurotransmitters (e.g., glutamate and monoamines) 
and hormones (e.g., glucocorticoids), as well as the secretion and responsiveness 
of neurons and glia to low levels of inflammatory cytokines, such as IL-1beta, IL-
6, and TNF, along with other mediators, such as complement factors 43, 
prostaglandins and neurotrophins 44. Under inflammatory conditions, the 
delicate physiological balance between immune and neural processes is 
disrupted; immune-competent cells within the brain parenchyma become 
activated and express high levels of pro-inflammatory cytokines and 
prostaglandins, which may lead to impairments in neural plasticity 19. 
In this thesis we studied the Ca2+-binding protein S100B, which has also been 
implicated in neural plasticity 45. S100B is mainly produced by astrocytes in the 
brain, and has both intracellular and extracellular functions, which are 
dependent on the concentration of this protein 46; while exerting neurotrophic 
effects at very low concentrations, it has been shown to have detrimental effects 
at high concentrations 47. A study in mice showed that overexpression of S100B 
resulted in activation of microglia and decreased numbers of astrocytes, as well 
as changes in hippocampal serotonin innervation 48. 
Neurotransmission 
Neurotransmission is the process where signaling molecules called 
neurotransmitters are released from presynaptic neurons and bind to receptors 
on postsynaptic cells in order to translate an electrical signal to a chemical. 
Released neurotransmitters may also activate autoreceptors in a feedback-manner 
among many. In that way, neurons can “talk” to each other and relay 
information. 
Several neurotransmitter systems have been implicated in neuropsychiatric 
conditions and mood disorders. The one most important for this thesis, and 
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one of the most excessively studied neurotransmitters in depression, is 
serotonin49. Serotonin, or 5-hydroxytryptamine (5-HT), is highly abundant in 
the periphery. In the CNS it is only released by serotonergic neurons, which 
have their cell bodies in the raphe nuclei of the brain stem. These neurons have 
projections to many different brain regions, including the amygdala, 
hippocampus, hypothalamus, prefrontal cortex (PFC), and septum. As the 
widely used antidepressants selective serotonin reuptake inhibitors (SSRIs) 
increase extracellular serotonin levels by blocking its reuptake from the synaptic 
cleft back into the presynaptic neuron, mood disorders have long been viewed 
as consequences of low serotonin levels. The mechanisms by which serotonin 
regulates mood appear a lot more complex however. 
There are several mechanisms by which the immune system has been shown to 
affect neurotransmission 50. One example is the activation of the indoleamine-
2,3-dioxygenase (IDO) enzyme 51. IDO is an enzyme expressed in multiple cell 
types, including macrophages, dendritic cells, microglia, astrocytes, and 
neurons52. The enzyme catabolizes tryptophan, the primary amino-acid 
precursor of serotonin, into kynurenine, thereby reducing the availability of 
tryptophan for serotonin synthesis. Pro-inflammatory cytokines have been 
shown to activate IDO, thereby causing lower levels of serotonin 51. 
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NEUROIMMUNOLOGY AND PSYCHIATRIC DISORDERS 
According to the World Health Organization, “Mental disorders comprise a 
broad range of problems, with different symptoms. However, they are generally 
characterized by some combination of abnormal thoughts, emotions, behaviour 
and relationships with others” 53. The symptoms in mental disorders can be 
divided into following categories: 
• Emotion (e.g., sadness, irritability, euphoria) 
• Somatic (e.g., sleep disturbance, fatigue, headache, pain) 
• Behaviour (e.g., tics, agitation, motor slowing) 
• Perception (e.g., hallucinations, delusions) 
• Cognition (e.g., memory impairment, inattention) 
Different types of mental disorders are characterized by a combination of 
symptoms from most, if not all, of these categories. Most mental disorders are 
very heterogenous; individuals diagnosed with the same psychiatric condition 
often display a different combination of symptoms, and the same symptoms can 
be due to different mental illnesses. Genetic studies suggest high heritability (i.e., 
the inherited contribution of genetic variance to trait variance) for many mental 
disorders 54, and several studies have implicated a polygenic overlap in a range 
of neuropsychiatric and mood disorders, including unipolar and bipolar 
depression, schizophrenia, and autism 55,56, suggesting shared etiology. These 
conditions often show nonspecific psychiatric symptoms that cross diagnostic 
boundaries, including behavioural abnormalities, intellectual disability, mood 
and anxiety, attention deficit, impulse control deficit, and psychosis 57. Another 
common denominator for various mental disorders is aberrations of the 
immune system; increased levels of pro-inflammatory cytokines, such as IL-
1beta, IL-6 and TNF have been reported in patients with schizophrenia, bipolar 
disorder, and depression 58, and pathway analysis by the Psychiatric Genomics 
Consortium identified histone modifications, synaptic density, and immune 
and neuronal signaling pathways in common for schizophrenia, depression and 
bipolar disorder 59. Further, genetic correlations between immune-related 
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disorders and a number of psychiatric conditions have been reported in a recent 
study combining data from several GWAS 60. 
Considering the highly sophisticated processes involved in brain development, 
any small disturbance may lead to alterations of the developing architecture and 
function. Infection with the Zika virus has been linked to microcephaly and 
other serious brain anomalies 61, demonstrating the detrimental effects that 
infections during pregnancy can have. However, these changes can also be more 
subtle, leading to neurodevelopmental disorders that are noted early in life, as 
well as mood disorders such as depression that may not be apparent until 
adulthood. An increasing body of evidence is connecting maternal immune 
activation with a broad spectrum of CNS disorders in humans 31,32,62. Possibly, 
it is not the specific pathogen causing an infection that determines the 
neurological and cognitive outcome in the offspring; the diversity of causes 
associated with increased risks of mental disorders suggests that general immune 
activation during gestation, rather than the type of pathogen, is associated with 
disturbances of fetal brain development causing debilitating effects later in life. 
This notion is supported by a recent study that associated fetal exposure to any 
maternal infection with increased risk of autism or depression diagnosis in the 
child 62. 
There are various ways in which changes in the immune system may lead to 
altered neurodevelopment and/or mental disorders (Figure 2). Maternal risk 
factors such as infection 62, psychosocial stress 63, genetic predisposition 64 and 
autoimmunity 65 can cause immune activation and changes in expression of 
cytokines, auto-antibodies against fetal proteins and/or other immune-related 
genes. This may lead to increased amounts of maternal markers crossing the 
placenta, including cytokines, immune cells, and stress hormones 31, possibly 
causing effects on the fetus such as aberrant development of the immune, 
neurotransmitter, and endocrine systems (e.g. altered stress response). 
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Figure 2. Schematic representation of potential pathways linking a dysregulated immune system to the 
etiopathogenesis of mental disorders. 
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Also cellular components of the CNS may be affected during development, 
including alterations of neurogenesis, (re)myelination, synaptic functions 
and/or brain homeostasis via astrocyte dysfunction 64. 
However, immune challenges during fetal development are not the only way the 
immune system may cause psychiatric symptoms; infection with streptococcal 
bacteria during childhood has been shown to elicit a rapid onset of psychiatric 
symptoms in a subset of children, including symptoms of obsessive compulsive 
disorder and tic-disorders, which could be relieved by e.g. antibiotic treatment66. 
This implicates also gene-environment interactions, i.e., that given a genetic 
vulnerability, exposure to certain environmental risk factors will increase the risk 
for disorder development. Genetic factors and/or prenatal immune challenges 
may be initial factors, increasing the susceptibility for “second hits”, such as 
immune challenges or psychosocial stress during childhood or adolescence, 
ultimately leading to changes in cognition and/or behaviour. 
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Major Depressive Disorder 
Affecting more than 300 million people worldwide, major depressive disorder 
(MDD; in this thesis interchangeably referred to as depression) is among the 
leading causes of disability worldwide, with a lifetime prevalence of at least 
16%67; yet the underlying mechanisms are far from understood. The symptoms 
include depressed mood, anhedonia (the inability to feel joy), feelings of 
worthlessness and inappropriate guilt, anxiety and recurrent thoughts of death 
and suicide, as well as psychomotor retardation, sleep disturbance and weight 
loss (for DSM-5 diagnostic criteria see Supplementary Table A) 68. The high 
mortality rate in patients with depression is not only caused by suicide, but also 
due to an increased risk for a number of other conditions, such as cardiovascular 
diseases and diabetes 5,69. 
Structural changes have been reported in several brain areas of depressed 
patients, including volumetric reductions of the hippocampus, basal ganglia and 
cortical regions are consistently found in depressed patients 70, with severity of 
depression being associated with greater impact on regional brain volumes. 
Changes in the amygdala have also been observed, but are more ambiguous than 
the changes in the aforementioned structures; while amygdala volumes earlier 
in the course of illness tend to be enlarged, a longer illness duration and severity 
tend to show volumetric reductions 70. 
Even though there are different pharmacological treatments available, not all 
patients can be treated successfully. Many of the current treatments for 
depression have in common the increase of neurotransmission at central 
serotonergic or noradrenergic synapses, leading to the monoamine hypothesis of 
depression, which suggests that depression is a direct consequence of an 
imbalance in monoamine neurotransmitters 71. Serotonin belongs to the 
monoamine family of neurotransmitters and is derived from the amino acid 
tryptophan. In the CNS, serotonin-containing neurons are clustered within the 
nine raphe nuclei, each of which projects to a different region of the brain. 
Amongst the most commonly prescribed antidepressants are SSRIs. As the name 
indicates, they inhibit the reuptake of serotonin from the synaptic cleft, thereby 
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increasing the availability of the neurotransmitter. Although the increase in 
serotonin levels is immediate 72, their therapeutic effects develop slowly, and it 
can take up to several weeks until patients feel relief from their symptoms 73. 
Therefore, the mechanism of action that mediates antidepressant effects is not 
believed to be due to the immediate elevation of extracellular serotonin but 
rather due to structural or functional adaptations of the CNS to chronically 
elevated serotonin levels. An increasing amount of evidence has led to several 
other hypotheses regarding the etiology of depression, involving the 
hypothalamic-pituitary-adrenal (HPA) axis and stress response, as well as 
inflammation and the immune system 51. 
Genetics and environment 
With a heritability estimate of approximately 30%, depression displays less 
contribution of inherited genetic variance to trait variance than many other 
mental disorders, e.g., autism or bipolar disorder 54. 
Genetic association studies, including linkage analyses, candidate gene studies, 
and genome-wide association studies (GWAS), have identified several loci for 
MDD 74. A plethora of genes have been identified in candidate gene association 
studies. However, a recent publication by Border et al.  investigated 18 candidate 
genes for depression that have been studied 10 or more times and examined 
evidence for their relevance to depression phenotypes; they concluded that “the 
study results do not support previous depression candidate gene findings, in 
which large genetic effects are frequently reported in samples orders of 
magnitude smaller than those examined here. Instead, the results suggest that 
early hypotheses about depression candidate genes were incorrect and that the 
large number of associations reported in the depression candidate gene 
literature are likely to be false positives.” 75. 
With regard to GWAS, three major genome-wide meta-analyses of MDD have 
been published by the Psychiatric Genomics Consortium 76–78, including a recent 
study by Wray et al., where they found 44 risk variants for depression, and 
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furthermore identified cytokine and immune response as one of the major 
pathways being involved 77. 
Environmental factors might play an important role in the etiology of 
depression, and gene-environment interactions have been implicated. However, 
also some of these findings were revoked by more recent studies that included 
significantly larger sample sizes; e.g., in one of the most highly cited papers in 
psychiatric genetics (>4700 citations), Caspi et al. (2003) reported a gene-
environment interaction of a functional polymorphism in the promoter region 
of the serotonin transporter gene and stressful life events between the age of 21 
and 26 in a cohort of Caucasians (n=847). They reported that individuals 
carrying the allele that is associated with lower transcriptional activity of the 
promoter exhibited more depressive symptoms, diagnosable depression, and 
suicidality in relation to stressful life events than individuals that were 
homozygous for the other allele. However, a study from 2011 using a comparable 
population (n=893) did not find a gene-environment interaction between this 
polymorphism, life stress, and mental disorders 79, and a recent publication that 
investigated the effect of previously implicated candidate gene polymorphisms 
across multiple, large samples (n>60000), found no effect of any of the 
“historical” candidate gene variants, including the serotonin transporter 
polymorphism 75. Furthermore, in a study from 2014, Peyrot et al. reported the 
effect of a genetic risk for depression to be significantly increased by exposure to 
childhood trauma 80, which they later controverted in a study where they found 
no significant interaction 81. Nonetheless, the fact that both genetics and 
environment play an important role in depression remains. Both animal and 
human studies have shown that early life exposure to prolonged levels of 
glucocorticoids and/or stress, such as childhood abuse, can induce epigenetic 
modifications on the glucocorticoid receptor gene that lead to alterations in 
expression and function of this receptor 82. Such epigenetic alterations have been 
associated with childhood abuse and with functional alterations in HPA-axis 
activity in depressed patients 83. The glucocorticoid receptor is expressed in 
almost every cell in the body and regulates the expression of genes controlling 
development, metabolism, and immune response, including IL-1beta, IL-6 and 
TNF 84. This repression of inflammatory cytokine expression causes the 
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immunosuppressive actions of glucocorticoid hormones. Antidepressants have 
been shown to activate the glucocorticoid receptor and to increase hippocampal 
neurogenesis 85, possibly via mechanisms including the immune system 86. 
Inflammation in depression 
Apart from the genetic findings pointing to a role of the immune system in 
depression (see above), also epidemiologic studies support that notion; a recent 
study including more than 1.5 million people found that exposure to any 
maternal infection during pregnancy increased risk of depression by 24% 62, 
supporting the role of early immune dysregulation in the etiopathology of 
depression. 
Further, alterations within the peripheral immune system have long been 
associated with mood disorders 9,87. Depressed patients have been found to have 
chronic peripheral immune activation with elevated cytokine levels 58,88,89. These 
cytokines can affect the CNS in various ways, as discussed above, causing e.g. 
elevated levels of pro-inflammatory cytokines in the brain parenchyma 19 and 
microglia impairment 90. Also peripheral levels of the Ca2+-binding protein 
S100B have been shown to be elevated in patients with depression 91,92, but 
central levels of S100B measured in the CSF of depressed patients provide 
contradicting results, with both increased 93 and decreased 94 levels being 
reported. 
Almost half of the patients undergoing cytokine treatment for the treatment of 
e.g. cancer or chronic viral infections have been reported to develop depressive 
symptoms as well as suicidal ideation 95, and interferon-alpha treatment in rats 
has been shown to induce depression-like behaviour accompanied by elevated 
levels of hippocampal quinolinic acid levels 96. Interestingly, a study in cancer 
patients receiving interferon (IFN)-alpha treatment showed that antidepressant 
treatment affected symptoms of depression, anxiety, and cognitive dysfunction 
more than symptoms of fatigue and anorexia 97, suggesting that sickness 
behaviour and cytokine-induced depression are mediated by different 
mechanisms. A proposed mechanism underlying this observation is the 
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stimulation of the enzyme IDO by pro-inflammatory cytokines 98, subsequently 
increasing levels of kynurenic acid in astrocytes and quinolinic acid in microglia. 
Together with glutamate released by activated microglia, quinolinic acid 
activates the N-methyl-D-aspartate (NMDA) receptors. Also, kynurenic acid has 
been shown to inhibit the release of glutamate, which, by extension, may 
downregulate neurotransmission of dopamine, whose release is regulated in part 
by glutamatergic activity 88. Activation of NMDA receptors and deficient 
dopaminergic neurotransmission may both result in depression symptoms and 
contribute to treatment resistant depression and/or suicidal behaviour. 
Several other immune aberrations have been reported in depressed patients, 
including signs of activation of the monocytic and lymphocytic arms of cell-
mediated immunity, characterized by increased numbers of peripheral blood 
leukocytes, monocytes, and neutrophils, and elevated circulating levels of and 
acute-phase proteins 99,100. 
Another factor that has been implicated in depression is psychosocial stress. As 
discussed above, hyperactivity of the HPA axis and increased levels of the 
glucocorticoid hormone cortisol are common observations in depressed 
patients. Cortisol activates glucocorticoid receptors, which in turn regulate the 
expression of neurotrophic factors, neuronal survival, neuronal excitability, 
neurogenesis and memory acquisition. High levels of cortisol may thus 
contribute to the manifestation of depressive symptoms by impairing these brain 
functions. Glucocorticoid receptors also regulate immune functions, exerting 
anti-inflammatory effects, and have been implicated in the therapeutic action of 
antidepressants 84. Cytokines can also cause glucocorticoid receptor resistance, 
i.e. the reduced ability of glucocorticoids to translocate into the nucleus, 
impeding the normally inhibitory effect of glucocorticoids on cytokine 
production and action, resulting in an increasing production of pro-
inflammatory cytokines and, subsequently, of stress hormones. 
Taken together, there are several pathways that can be affected by immune 
mediators, which in turn can cause depression symptoms. These include 
activation of IDO and the subsequent generation of neuroactive tryptophan 
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metabolites, as well as glucocorticoid receptor resistance, which amplifies the 
inflammatory response and leads to excessive production of stress hormones.  
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Bipolar Disorder 
As in major depressive disorder, individuals suffering from bipolar disorder 
experience depressive episodes with lowered mood, anhedonia, guilt and 
thoughts of death and suicide. Unlike unipolar depression, however, bipolar 
disorder is characterized by episodes of mania or hypomania in addition to 
depressive episodes. Bipolar disorder has frequent psychiatric comorbidity 101, 
and is strongly related to both depression and schizophrenia; with the 
introduction of the DSM-5 in 2013, bipolar disorder has moved further away 
from MDD and more towards schizophrenia 68. The data in this thesis was 
collected before the release of the DSM-5, with diagnosis being based on the 
fourth text-revised edition from 2000 (DSM-IV) 102. However, DSM-IV and 
DSM-5 resemble each other greatly with respect to the diagnosis criteria for 
bipolar disorder (for DSM-5 diagnostic criteria see Supplementary Table B) 68.  
Bipolar disorder affects approximately 60 million people worldwide 53, although 
this number might be an underestimation, due to misdiagnosis and reluctance 
of the affected to admit to symptoms. As for most psychiatric disorders, the 
etiology of bipolar disorder is largely unknown. However, it is highly heritable, 
with twin studies reporting up to 85% heritability 103 
Depending on the symptoms, bipolar disorder can be divided into, amongst 
others, type I and II. Bipolar disorder type I is defined as having at least one 
manic episode, which lasts for at least seven days (or if it leads to hospitalization). 
Often, patients with bipolar type I have intermittent manic and depressive 
episodes, although according to the DSM one manic episode without depressive 
episodes is enough to classify the mood disorder as bipolar type I. Manic 
episodes are characterized by elated mood which may include euphoria, but the 
predominant mood is often irritable rather than elevated. In case of psychotic 
features, the episode is, by definition, manic, and not hypomanic. Bipolar 
patients experiencing a manic episode may experience inflated self-esteem and 
engage in e.g. multiple overlapping new projects, which are often initiated with 
little knowledge of the topic, feel a decreased need for sleep, and display rapid, 
pressured speech and/or distractibility. 
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Bipolar type II is defined as intermittent hypomanic and depressive episodes, 
both being a requirement for diagnosis. Hypomania is characterized by very 
similar features as mania, but in general has less impact on global functioning 
and typically, the hypomanic episodes themselves do not cause impairment. 
However, bipolar type II is no longer thought to be a “milder” condition than 
bipolar type I, as it is characterized by a significant amount of time spent in 
depression, as well as a persistent pattern of unpredictable mood changes and 
fluctuating, unreliable interpersonal or occupational functioning, causing 
serious impairment in work and social functioning 68. 
Depressed mood is the predominant state in bipolar disorder, with depression 
being three times more prevalent than mania or hypomania over time 104. Mood 
episodes usually have a gradual onset over days to weeks, and varying duration; 
manic episodes may last as long as three months if left untreated, and depressive 
episodes normally have a duration of at least four months if left untreated. 
Although alterations in mood and general level of activity are the main features 
of bipolar disorder, other symptoms include changes in motivation, cognition, 
perception, and motor activity. Also, patients may display normal mood and be 
free from symptoms between episodes, a state known as euthymia. However, 
euthymic patients often still display symptoms such as subthreshold mood 
symptoms, affective dysregulation, psychomotor disturbances, impaired social 
capacity, and neurocognitive impairments. With regard to cognitive 
impairments, studies have shown e.g. impaired attention, dysfunction in 
episodic memory, delayed verbal memory, and impairments in executive 
functioning, response inhibition, and psychomotor speed 105–107. A study 
comparing depressed patients with bipolar disorder to patients with MDD 
found the same type of cognitive dysfunction in all patients, but to a much 
higher extent in bipolar patients 108, suggesting that frontal lobe impairment is 
more marked in bipolar than unipolar patients during depressive episodes. 
Structural and neurophysiological changes are also part of bipolar disorder; 
several studies have reported cortical abnormalities 109–111, and a shape 
alterations of the striatum have been seen in bipolar patients as compared to 
healthy controls 112. A review comparing findings from magnetic resonance 
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imaging (MRI) studies in patients with bipolar disorder or MDD found several 
structural and functional alterations in emotion- or reward-processing neural 
circuits 44. They concluded that activation patterns differed in several brain 
regions, including the amygdala, anterior cingulate cortex, PFC, and striatum, 
during emotion-, reward-, or cognition-related tasks, and that grey matter volume 
differed in the amygdala, anterior cingulate cortex, hippocampus, and 
dorsolateral PFC, which was also found to be thinner in bipolar patients 
compared to patients with unipolar depression 44. Interestingly, markers of 
immune activation have been associated with cortical thickness in patients with 
bipolar depression 113. 
In order to explain the progressive pathophysiological processes accompanying 
bipolar disorder, a neuroprogressive model has been proposed, adding several 
components to the earlier implicated role of monoamines and messenger 
systems. These components include i.a. changes in neurotrophins, 
corticosteroids and inflammatory cytokines 114,115.  
Genetics and environment 
Heritability measures for bipolar disorder are consistently high; some studies 
have reported heritability of 85% for the disorder 103, and up to 93% have been 
reported for bipolar type I 116. A population-based study of schizophrenia and 
bipolar disorder found increased risks of both schizophrenia and bipolar 
disorder to first degree relatives of probands with either disorder, with 
heritability estimates of 59% for bipolar disorder, and a unique genetic effect 
(i.e. not shared with schizophrenia) of 31% 117. Several genome-wide studies have 
investigated genetic associations in bipolar disorder, describing loci implicated 
in the disorder. A very recent GWAS by Stahl et al. reports 30 genome-wide 
significant loci, including 20 newly identified loci, in genes coding for e.g., ion 
channels, neurotransmitter transporters and synaptic components 118; they 
furthermore found bipolar type I to be strongly genetically correlated with 
schizophrenia, driven by psychosis, whereas bipolar type II was more strongly 
correlated with MDD. Shared genetic risk factors between bipolar disorder and 
schizophrenia have also been suggested by other studies; e.g., variants in the 
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CACNA1C gene encoding a voltage-gated calcium channel subunit have been 
associated with both disorders 118–120. 
Also immune markers have been implicated by genetic studies; haplotype studies 
have found associations between bipolar disorder and human leucocyte antigen 
(HLA) genes 121, suggesting that the HLA system may mediate some of the 
immune dysregulations observed in bipolar patients. The HLA gene locus 
encodes the human versions of three different classes of MHC proteins, which 
are involved in various immune functions and have been associated 
with autoimmune, infectious, and inflammatory diseases 122. Furthermore, 
bipolar disorder has been associated with variants in the IL-1beta gene cluster123. 
Inflammation in bipolar disorder 
Immune dysfunction has been implicated in the etiology and pathophysiology 
of bipolar disorder on various levels, including findings in epidemiological 
studies, as well as peripheral and post-mortem brain studies. Replicated 
epidemiological studies have demonstrated that bipolar disorder has high rates 
of inflammatory medical comorbidities, including autoimmune disorders, 
chronic infections and cardiovascular disease 124. 
Increased levels of a plethora of cytokines have been found in both blood and 
plasma of patients with bipolar disorder 58,114,125, including the proinflammatory 
cytokines IL-1beta, IL-6 and TNF, but also anti-inflammatory markers. Also 
increased peripheral levels of the acute phase protein corticotropin releasing 
protein and complement factor C3 have been associated with bipolar 
disorder126,127. With regard to central cytokine levels, a post-mortem study found 
significantly higher mRNA and protein levels of IL-1beta and its receptor in the 
frontal cortex of bipolar individuals 128. This cytokine has also been shown to be 
increased in the CSF of the bipolar patients 129 included in this thesis, with levels 
being even higher in patients that had experienced at least one 
manic/hypomanic episode during the previous year. 
Central levels of neuroinflammatory markers have been associated with 
cognitive performance in patients with bipolar disorder but not in healthy 
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controls 130, suggesting that inflammation may be involved in the underlying 
causes for cognitive decline in bipolar individuals. Bipolar patients are 
furthermore reported to have higher rates of medical conditions with a serious 
inflammatory component, including cardiovascular diseases, diabetes, and 
rheumatoid arthritis 131. 
Epidemiological data regarding maternal immune activation and bipolar 
disorder is controversial however; although an earlier study reported a nearly 4-
fold increase in risk of bipolar disorder after exposure to maternal influenza 
infection at any time during pregnancy 132, a very recent study found no 
associations between maternal immune activation and bipolar disorder or 
diagnosis of psychosis, including schizophrenia 62. 
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Autism Spectrum Disorder 
Autism spectrum disorder (ASD), hereafter interchangeably referred to as 
autism, is a neurodevelopmental disorder characterized by early-onset difficulties 
in social communication (both verbal and non-verbal) and unusually restricted, 
repetitive behaviour and interests (for DSM-5 diagnostic criteria see 
Supplementary Table D). With a worldwide prevalence of about 1% it affects 
approximately four times more males than females 133, and has a high 
comorbidity with other neuropsychiatric disorders, such as attention-deficit 
hyperactivity disorder, tic disorder and anxiety disorders 134,135. Neuroimaging 
studies have revealed structural differences in the brains of children with autism; 
cerebral cortical overgrowth has been reported 136, and a recent mega-analysis, 
i.e., combining original data of several studies, in a large sample (n=1571 
patients, 1651 controls) found autism to be associated with smaller subcortical 
volumes of the pallidum, putamen, amygdala, and nucleus accumbens, as well 
as increased cortical thickness in the frontal cortex and decreased cortical 
thickness in the temporal cortex 137. A post-mortem study furthermore revealed 
higher number of neurons in the PFC of male children with autism, although 
in a very small sample (n=7 patients, 6 controls) 138. 
With respect to the etiology of autism, no single cause has been identified. For 
decades, autism was believed to be caused by lack of affection, also referred to as 
“emotional refrigeration”, of the parents to children with autism. This notion 
wasn’t abandoned until e.g., Michael Rutter and Lorna Wing reviewed the 
biological basis for autism, renouncing the concept of autism as an infantile 
psychosis or psychogenic disease caused by emotional coldness of the parents, 
and emphasizing instead the role of language or coding problems caused by 
cognitive and perceptual defects, as well as genetic factors 139,140. Nowadays, both 
genetic and environmental factors have been attributed influence and will be 
discussed in more detail in the chapter Genetics and environment. 
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History of autism diagnostics 
The term “autism” was introduced in 1911 by the psychiatrist Eugene Bleuler to 
describe schizophrenic patients who withdrew from reality and became self-
absorbed. Childhood conditions that today would be referred to as ASD were 
labeled “childhood schizophrenia” 141, and the first (1952) and second (1968) 
editions of the Diagnostic and Statistical Manual of Mental Disorder 
(DSM)142,143 viewed autism as a form of childhood psychosis. 
In 1943 and 1944, respectively, the Austrian-American psychiatrist Leo Kanner 
and the Viennese pediatrician Hans Asperger, independently of each other 
published papers on children displaying symptoms of childhood autism 144,145. 
Their descriptions contained several similarities such as higher incidence in 
males, lack of interest for other people’s emotions or thoughts, communication 
deficits and repetitive behaviours. Asperger´s children were, however, less 
severely disabled compared to those described by Kanner, and Asperger noted a 
vast vocabulary and high intelligence in some of the children, coupled with 
narrow interests. 
It was not until 1980 and the publication of the third edition of the diagnostic 
manual (DSM-III) 146, that infantile autism became an independent diagnosis 
under the general category of pervasive developmental disorder (PDD). When 
the DSM-IV was released in 1994 102, infantile autism was renamed autistic 
disorder, and the umbrella term PDD included the diagnoses autistic disorder, 
Asperger’s syndrome, pervasive developmental disorders not otherwise specified 
(PDD-NOS), childhood disintegrative disorder and Rett’s disorder. In the DSM-
IV, the inclusion criteria were broadened compared to DSM-III, and it included 
twelve diagnostic symptoms for autistic disorder (for DSM-IV diagnostic criteria 
see Supplementary Table C). These symptoms were organized in accordance 
with a triad of impairments that had been suggested by Wing et al. in 1981 147: 
(1) impairments in social interaction, (2) impairments in communication, and 
(3) restricted, repetitive and stereotyped patterns of behaviour, interests and 
activities, each containing four individual symptoms. 
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In 2013, the fifth edition of the DSM was released (DSM-5) 68. In this latest 
revision of the diagnostic manual, the diagnoses previously assembled under the 
umbrella term pervasive developmental disorders (PDD) have been merged into 
the single diagnosis of ASD (for DSM-5 diagnostic criteria see Supplementary 
Table D), without a definition of subtypes and with severity measured within 
the broader diagnosis. Furthermore, the triad of symptoms for autism diagnosis 
was merged into two domains: the social interaction and communication 
domains were combined into a single domain. Atypical language development 
was removed from the autism diagnosis criteria and classified as a co-occurring 
condition, since large variation in language is a characteristic of autism 148. This 
new diagnosis of “social (pragmatic) communication disorder” is defined by 
difficulties with social uses of both verbal and non-verbal communication, but 
does otherwise not meet criteria for autism. 
With the DSM-5, a conceptual change of the diagnostics was introduced: while 
the previous diagnostics regarded all disorders included under the umbrella term 
PDD as discrete disorders, the new diagnostics of the DSM-5 include but one 
ASD diagnosis with varying degrees of severity. This concept was proposed 
decades ago 149, suggesting a continuum of symptoms that are also present in 
varying degrees in the general population. 
Autistic-like traits 
While autism can be construed as the lower-most extreme end of a continuum 
of social abilities, individuals might display milder phenotypes related to the 
autism characteristics that do not meet the diagnostic criteria for ASD: these 
traits are referred to as autistic-like traits (ALTs) and represent the boundary 
between autism and normality. A nation-wide study reported that ALTs occur 
to some extent in 35% of the whole population 150, and an aggregation of ALTs 
in close relatives of individuals with autism has been reported 151. Thus, autism 
has been suggested to represent the extreme end of a normal distribution of 
ALTs, with genetic factors playing an important role in both. Although a 
genome-wide association study failed to identify single nucleotide 
polymorphisms (SNPs) common to autism and ALTs 152, several studies have 
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suggested a shared genetic etiology between autism and ALTs across normal 
variation and the extreme ends 153,154. Furthermore, a study using a large autism 
consortium and population-based genomic data sets demonstrated that there is 
a genetic correlation between certain ALTs concerning social and 
communication skills and autism 155, and a recent GWAS comparing ALTs in a 
large cohort from the general population with results from the Psychiatric 
Genomics Consortium GWAS of autism further supported this notion 156. 
Bralten et al. identified several polymorphisms in genes encoding proteins 
involved in neurite outgrowth to be shared between ALTs and autism, including 
the MET receptor tyrosine kinase gene (MET). These findings suggest that 
multiple types of genetic risk factors for autism influence a continuum of 
behavioural and developmental traits, the extreme end of which can result in 
autism or other neuropsychiatric disorders. 
Genetics and environment 
Autism has one of the highest heritability estimates amongst mental disorders, 
with twin studies suggesting a heritability of 80-98% 135,157. For approximately 
5% of autistic cases where autism co-occurs with a known Mendelian genetic 
syndrome, such as Fragile X syndrome, tuberous sclerosis or Rett syndrome, the 
genetic cause has been identified. This is known as syndromic autism. However, 
this constitutes only a small proportion of individuals with autism, and for the 
majority the genetic cause has not been identified – this is referred to as idiopathic 
autism. In autism research, syndromic autism disorders are used as "model 
disorders" for idiopathic autism. Affected biological pathways are beginning to 
be elucidated through extensive analyses of these genes. To give an example, the 
fragile X syndrome is caused by mutations in the FMR1 gene and Rett disorder 
by mutations in the MECP2. Although the disrupted gene has been identified, 
different mutations can occur in these genes. Depending on where in the gene 
the mutation occurs, protein function might be affected differently. Thus, the 
clinical presentation of the genetic syndromes can be highly heterogeneous, 
highlighting the complex relationship between genotype and phenotype. If we 
can understand how the loss of function of the affected genes can lead to 
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behavioural alterations such as deficits in social communication, it will help us 
to better understand the underlying biology of autism. 
Despite the high heritability estimates, the underlying genetics of the disorder 
are characterized by large heterogeneity and complexity; autism, as well as 
virtually all other mental health disorders, are now generally accepted to not be 
due to one single or even a few genetic causes but precipitated by a plethora of 
genetic factors and/or largely unknown gene-environment interactions. No 
single gene leads to autism every time it is mutated, and genetic studies have so 
far implicated up to 1000 genes in autism 158. In addition to this locus 
heterogeneity a high degree of pleiotropy (i.e., one gene affects more than one 
phenotype) has been shown in variants linked with autism, further adding to 
the complexity of the genetic etiology. Both rare mutations with large individual 
effects and common variants with small effect sizes have been implicated 158. 
Rare mutations can occur in the form of the already mentioned Mendelian 
genetic syndromes, chromosomal abnormalities, rare copy number variations 
and de novo and transmitted single nucleotide variants 159. Although common 
variants (e.g. SNPs with an allele frequency of >5% in the general population) 
have been proposed to account for the majority of autism liability 160, they have 
small individual effects, and GWAS have, until very recently, been largely 
unsuccessful at identifying mutations with a large enough effect size to reach 
genome-wide significance level. This lack of results might possibly have been due 
to limited sample size, as recent studies with markedly larger samples have found 
significant associations of several common variants with autism 161,162; the 
identified loci were mainly in genes involved in the regulation of brain 
development and neuronal function, and several of these genes have previously 
been linked to autism risk in studies of de novo and rare variants, as well as with 
risk for depression and schizophrenia 77,161. Their findings furthermore support 
the notion that the heterogeneity seen in the clinical presentation of autism is 
reflected in the genetic architecture of subtypes found in the spectrum 163; 
common variants may have a greater impact in high-functioning autism, while 
de novo mutations like copy number variants and gene-disrupting point 
mutations are more present in subtypes including severe impairments and 
intellectual disability. The complexity of the genetic etiology for autism has only 
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been increased by the results from genome wide technologies; however, several 
autism-related genes encode components of the immune system, such as the  
MET gene, an important regulator of immunity and brain development 164, and 
the HLA locus, which encode the MHC genes in humans. Variants in all three 
classes of MHC genes have been reported to enhance autism risk 165. However, 
as with many other autism-related genes, these associations are not unique to 
autism; they are also associated with other neurodevelopmental disorders and 
autoimmune disorders 166, which occur at higher rates in the relatives of 
individuals with autism 167,168.   
Although not reaching significance level after correction for whole genome 
multiple testing, the findings reported by Grove et al. point to a role of the 
immune system in autism; tissue-specific analysis of genes revealed that immune 
related genes were among the top three affected systems (together with brain 
tissues and stem cells) before correction for multiple testing 169. 
Despite the high heritability suggested by twin studies, the fact that monozygotic 
concordance rates (i.e. the risk for a monozygotic co-twin receiving the same 
diagnosis as the proband) never reach 100% suggests an impact of 
environmental factors. A large role for shared environmental effects has been 
proposed in a twin study by Hallmayer et al. 170, but this is however not supported 
by all studies 157. It seems that both the genetic background as well as epigenetic 
mechanisms and gene-environment interactions, which are dependent on the 
context of environmental risk factors, play an important role in the etiology and 
pathophysiology of autism. Environmental risk factors that have been identified 
include, amongst others, prenatal exposure to toxicants 171 and maternal 
infections 172, both of which lead to altered levels of inflammatory mediators. 
Considering the role of the immune system in brain development 34, altered 
immune function might impair a wide array of neurodevelopmental processes 
such as neurogenesis, proliferation, apoptosis, synaptogenesis and synaptic 
pruning, making it a crucial but complex biological pathway in the etiology of 
autism in at least a subset of cases, which will be discussed in the following 
chapter. 
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Inflammation in autism 
Almost half a century ago a connection between congenital rubella infection and 
autism was noted 173 that seemed preventable by rubella vaccination 174. Since 
then numerous other epidemiological studies have found associations between 
maternal immune activation and autism, including a Danish population cohort 
study linking viral infection in the first trimester and bacterial infection in the 
second trimester, that required hospitalization, to an increased risk of an autism 
diagnosis later in life 175. A meta-analysis of more than 40000 autism cases from 
15 different studies 176 found an association between general infection and 
autism, as well as a more pronounced risk of autism in the offspring of patients 
who required hospitalization for the treatment of infection during pregnancy, 
with type of infectious agent and time of infection during pregnancy affecting 
the risk. Most recently, a study including more than 1.5 million people found 
that exposure to any maternal infection during pregnancy increased risk of 
autism by 79% 62. A plethora of animal maternal infection models have shown 
consistent results, establishing autism-relevant atypical behaviours 172, further 
confirming a strong impact of maternal immune activation in the etiology of 
autism. 
However, studies investigating the effect of maternal immune activation are not 
the only evidence linking the immune system to autism. A number of 
immunological factors have been linked to autism, including cell-surface 
proteins such as the HLA complex 177,178, and a variety of clinical studies have 
linked cytokines to autism, for review see 164,179–181; elevated levels of several pro-
inflammatory cytokines have been reported in the serum and blood of autistic 
individuals, including IL-1beta, IL-6, TNF, and IFNg 182–185, and changes in 
cytokine and other immune mediator marker expression have also been 
reported in post-mortem brain studies 186–188. 
However, lower levels of immune markers have also been reported; a study 
investigating peripheral cytokine levels in children with autism found that lower 
cytokine levels were significantly associated with increased severity of autism-
related symptoms 189. They furthermore found that boys and girls had 
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significantly different immune profiles. These results add a new dimension to 
the sex-differences observed in autism. In addition to findings showing that 
females carry significantly more mutations in neurodevelopmental-related genes 
that males with the same symptoms, supporting a concept referred to as “the 
female protective model” 190, the study by Masi et al. suggests that also differences 
in immune activity might be a contributing factor to the higher incidence of 
autism in males. 
To date, there is no genetic test that can diagnose autism. However, specific 
immunologic assays have been tested in the diagnostic procedure of autism, 
using a signature of differentially co-expressed genes that were enriched in 
translation and immune function/inflammation, identifying boys with autism 
with 83% accuracy 191. This study suggests that genomic immune markers might 
contribute to a clinical test that could be implemented in diagnostic settings. 
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AIMS 
The overall aim of this thesis is to investigate the role of the immune system in 
brain function, both in animal model and in human populations. We 
hypothesize that inflammatory mediators are significant for psychiatric 
conditions by modulating e.g. the development of the brain and 
neurotransmission. 
Paper I 
The aim of “Expression of inflammatory markers in a genetic rodent model of depression” 
was to study behaviour in the open field test and forced swim test, as well as to 
investigate central gene expression in a rat model of depression; the Flinders 
sensitive line (FSL), and its control the Flinders resistant line (FRL); in response 
to peripheral immune stimulation by the bacterial endotoxin 
lipopolysaccharide. 
Paper II 
The aim of “Effects of chronic escitalopram treatment on the expression of inflammatory 
markers in the Flinders rat model of depression” was to study the effects of chronic 
administration of the antidepressant escitalopram on central expression of 
immune-related genes in the FSL depression model and its control. 
Paper III 
The aim of “Associations between autistic-like traits and polymorphisms in NFKBIL1” 
was to investigate associations between autistic-like traits and polymorphisms in 
two candidate genes that are central to immune functions; NFKB1 and NF-κB 
inhibitor-like protein 1 (NFKBIL1). 
Paper IV 
The aim of “Influence of variations in IL1B on brain region volumes in bipolar patients 
and controls” was to investigate associations between polymorphisms in the gene 
coding for the pro-inflammatory cytokine interleukin-1 beta (IL1B) and bipolar 
disorder, as well as whole-brain grey matter volume and volumes of several brain 
regions shown to be of importance in mood disorders. 
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RESULTS 
Paper I 
The main findings of this paper are: 
• FSL rats displayed higher locomotor activity in the open field 
test than their controls, and LPS decreased locomotor activity 
in both rat lines 
• FSL rats showed higher immobility in the forced swim test 
when compared with FRL rats, and LPS increased immobility 
in both rat lines 
• mRNA levels of two genes were lower in FSL compared to FRL 
rats: S100b in all investigated brain regions, and C3 in all 
investigated brain areas apart from the hypothalamus 
• mRNA levels of Htr2a were higher in the hippocampus of FSL 
rats compared to FRL rats 
• LPS had no effect on S100b expression levels, but increased 
levels of C3, Il1b, Nfkbia, Timp1 and Tnf in all investigated 
brain regions, as well as of Il6 in the hippocampus and 
hypothalamus and of Mmp9 in the hypothalamus and striatum 
in both rat lines 
• there was no interaction effect between rat line and LPS 
  
In Paper I, FSL rats had lower mRNA levels of S100b and C3 in almost all 
investigated brain regions, as well as higher Htr2a mRNA levels in the 
hippocampus. There was no difference, neither behavioural nor in 
transcription levels, between FSL and FRL animals in response to peripheral 
immune stimulation. 
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Paper II 
The main findings of this paper are: 
• mRNA levels of S100b were lower in FSL compared to FRL 
animals in all investigated brain regions, replicating our 
findings from Paper I 
• mRNA levels of Htr2a were higher in the hippocampus of FSL 
compared to FRL rats, replicating our findings from Paper I 
• The following findings from Paper I were replicated regarding 
mRNA levels in FSL compared to FRL animals: lower levels of 
C3 in the PFC and striatum, Il1b in the hippocampus, Mmp9 
in the PFC and Timp1 in the hippocampus, albeit only 
nominally significant 
• Escitalopram treatment lowered mRNA levels of S100b and 
Htr2a in the amygdala and hypothalamus of FSL and FRL 
animals 
• An interaction between rat line and treatment was found for 
Il18 in the hippocampus; post-hoc analyses revealed that FSL 
rats had lower Il18 levels than FRL rats, and that escitalopram 
lowered Il18 expression in FRL but not FSL animals 
  
In Paper II, we replicated findings from Paper I regarding differences in gene 
expression of e.g., S100b and Htr2a, between FSL and FRL rats. Escitalopram 
treatment lowered S100b and Htr2a mRNA in the amygdala and 
hypothalamus. 
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Paper III 
The main findings of this paper are: 
• The polymorphisms rs2239707 and rs2230365 in NFKBIL1 
showed associations in the case-control analysis, i.e. with a 
validated proxy for clinical diagnosis of ASD; for rs2230365, 
the finding replicates an earlier association found between this 
variant and autism in an independent genome-wide association 
study 
• rs2230365 was associated with the autistic-like trait of language 
impairment 
  
In Paper III, two polymorphisms in NFKBIL1 were associated with a probable 
diagnosis of ASD, with the finding concerning rs2230365 replicating earlier 
associations between this variant and autism. This polymorphism was 
additionally associated with language impairment. 
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Paper IV 
The main findings of this paper are: 
• Genotype distribution of the investigated polymorphisms in 
IL1B was not different between bipolar patients and controls  
• The T allele at rs16944 and the C allele at rs1143627 were 
associated with increased volume of the left putamen in 
patients and controls 
• Several of the investigated polymorphisms were nominally 
associated with volume of the globus pallidus, putamen, and 
thalamus in both patients and controls 
• No associations were seen between IL1B variants and volume 
of the amygdala, caudate nucleus, hippocampus, or nucleus 
accumbens  
 
In Paper IV, two polymorphisms in Il1B were associated with increased 
volumes of the left putamen in both bipolar patients and controls. No 
association was found between bipolar disorder and variants in IL1B. 
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DISCUSSION 
ANIMAL STUDIES (PAPER I & II) 
Behaviour (Paper I) 
Although the increased locomotor behaviour of FSL compared to FRL rats in 
the open field test (Paper I) is not in line with the general understanding that 
FSL rats move less than FRL rats, the observed increase in immobility of FSL 
rats in the forced swim test confirms the more depressive-like phenotype of the 
FSL animals. The behavioural responses to LPS, i.e., reduced locomotor activity 
in the open field test and higher immobility in the forced swim test, suggest 
acute sickness behaviour of the animals, as was expected six hours after 
endotoxin administration 12. 
Effect of rat strain on central gene expression (Paper I & II) 
The Ca2+-binding, astrocyte specific protein S100B has been associated with a 
wide spectrum of diseases, such as neurodegenerative diseases, 
congenital/perinatal disorders, and psychiatric disorders 46. It is used as a 
biomarker of active neural distress, although the wide spectrum of pathological 
conditions in which S100B is involved markedly reduces its specificity. 
With regard to psychiatric disorders, altered levels of S100B have been shown 
in a plethora of studies; increased peripheral levels have been reported in 
patients with autism 182,192, schizophrenia 193 and mood disorders 93,194,195. 
Interestingly, high peripheral S100B baseline levels have been positively 
associated with response to antidepressant treatment 196. Post-mortem studies 
have also reported alterations of central S100B levels in depression, bipolar 
disorder, and schizophrenia 197–199. However, the findings are often 
contradicting, with both higher and lower levels being reported, and it is unclear 
whether central levels of S100B are correlated with peripheral levels 200. 
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S100B has also been implicated in neurotransmission and central immune 
functions. Pro-inflammatory cytokines such as IL-1beta, IL-6 and TNF stimulate 
secretion of S100B 201, and S100B in turn induces expression of pro-
inflammatory cytokines in both neuronal and microglial cells 202,203. Chronic 
S100B overexpression resulted in decreased numbers of mature, stable 
astrocytes, as well as in activation of microglia in mice 48. These data suggest that 
S100B may cause cell-type specific gene-regulatory events leading to long-lasting 
activation of immune cells and cytokine production, further supporting a pro-
inflammatory regulatory role of S100B on cells of the CNS 204.  
The difference in basal expression levels of S100B between the FSL and FRL rat 
lines observed in Paper I and II—that is, lower levels in FSL—might be due to a 
differently regulated immune system in the two rat lines that may lead to glial 
pathology and neurodevelopmental effects causing functional and/or structural 
differences between them. However, it is not obvious that S100B is crucial for 
the behavioural differences seen in the FSL animals and their controls; given the 
human S100B literature 91, one could hypothesize that the levels of this protein 
should be higher in the FSL animals, even though the literature regarding S100B 
and psychiatric disorders is not conclusive yet. 
Our findings in Paper I and II suggest that the Flinders rat may be a suitable 
model in the study of the functional implications of altered S100B levels in 
depression-like behaviour. However, certain points should be investigated in 
order to further validate this animal model as a proper tool with which to study 
the role of S100B in depression. First, peripheral S100B levels have been shown 
to be elevated in two other rat depression models 200, but need to be investigated 
in the FSL rat. Second, since we measured mRNA levels, we cannot be certain 
that these reflect protein levels, and this should be addressed in future studies. 
Third, the downregulation of S100B mRNA levels in FSL compared to their 
controls was much stronger in Paper I than Paper II. The reason for this is not 
known, and this should be investigated in forthcoming studies. Finally, it needs 
to be established whether the lower levels of S100B are part of the etiology of 
depressive-like behaviour, a consequence of it, or a finding not related to 
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behaviour in this animal model. Furthermore, additional studies are warranted 
with respect to the influence of S100B on neurotransmission. 
We also found lower mRNA levels of the complement factor C3 in FSL 
compared to FRL animals in both Paper I and II. Complement activity and 
especially C3 are highly involved in pruning of nonfunctional synapses during 
brain development 40, and disruption of C3 signaling results in sustained deficits 
in synaptic connectivity 22. C3 has also been implicated in the pathophysiology 
of depression in humans, as depressed patients had lower CSF levels of the 
complement component compared to healthy subjects 205, which is in line with 
our results. However, it should be noted that we were unable to replicate all 
findings regarding C3 from Paper I in Paper II. 
The upregulation of the serotonin receptor 5-HT2A mRNA in the hippocampus 
of FSL compared to FRL rats observed in both Paper I and II is in line with 
earlier experimental studies 206,207 and further supports a role of serotonin and 
the 5-HT2A receptor in the depression-like behaviour of this animal model. 
Furthermore, our results are compatible with findings in humans; increased 
numbers of 5-HT2A receptors have been reported in the brains of depressed 
patients 208,209 and suicide victims 210–212. Our results underline the suitability of 
this model to further study the impact of serotonin and its receptors in the study 
of depression. 
Additionally, we found differences in the expression levels of the matrix 
metalloproteinase MMP-9 and its inhibitor tissue inhibitor of matrix-
metalloproteinases (TIMP-1) between FSL and FRL rats. MMP-9 plays an 
important role in the remodeling of the extracellular matrix via degradation of 
proteins, and both MMPs and their physiological antagonists TIMPs are crucial 
for CNS development and have beneficial roles in the healthy adult brain, such 
as regulating synaptic and structural plasticity. However, aberrant expression of 
MMP-9 has been implicated in CNS diseases, contributing to 
neuroinflammation via several mechanisms such as disruption of the blood-
brain barrier, cytotoxicity and demyelination 213. Candidate gene studies have 
proposed a role of MMP-9 in psychiatric disorders such as schizophrenia and 
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bipolar disorder 214, and genetic variability in the MMP-9 gene has been 
associated with personality traits 215, suggesting its involvement in psychiatric 
morbidity and mental functions. However, although our finding that MMP-9 is 
lower in the PFC of FSL than FRL rats is consistent in Paper I and Paper II, it 
is only borderline significant and should be interpreted with caution. 
Moreover, we found lower mRNA levels of IL-1beta in the hippocampus and 
raphe nuclei, and of IL-18 in the amygdala and hippocampus, of FSL rats 
compared to their control, but no significant strain effect for any of the other 
investigated pro-inflammatory cytokines. 
IL-1beta has been implicated in the pathophysiology of depression with respect 
to several mechanisms, including neurogenesis and the serotonergic system 216. 
IL-18, also called interferon-gamma-inducing factor, is a potent inducer of TNF 
and other cytokines and chemokines 217. Il-18 is produced in the brain by several 
cell types, such as astrocytes, microglia, and neurons 218 and is tightly 
regulated219. Promoter variants in IL-18 that have been associated with increased 
levels of IL-18 were more common in individuals that developed a depressive 
episode in response to stressful life events 220, and central levels of IL-18 have 
been found to be elevated in a post-mortem study of prefrontal cortex tissue of 
depressed patients 221, suggesting that this cytokine is regulated differently in the 
animal model than humans. 
It should be noted that the levels of all investigated cytokines, as well as some 
other immune-related markers, had a tendency to be lower in FSL compared to 
FRL rats, showing nominal significances in many of the investigated brain 
regions. This is in contrast with a number of human studies showing elevated 
levels of e.g. IL-1beta, IL-6, and TNF in the periphery of depressed patients 222,223. 
The reason for the discrepancy in these findings is not clear, but, as mentioned 
above, the expression of cytokines might be regulated differently in the CNS 
compared to the periphery 224. However, human data regarding central cytokine 
levels is more controversial; increased levels of IL-6 have been reported in the 
CSF of suicide attempters 225, and depressed patients showed both elevated levels 
of IL-1beta, and lower levels of IL-6 226. A possible explanation for the lower 
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central mRNA levels of various immune mediators in FSL rats might be 
compensatory mechanisms, or an overall downregulation in central gene 
expression. 
However, our findings that FSL and FRL rats displayed no differences in 
cytokine mRNA levels, apart from IL-1beta and IL-18, suggest that the 
depressive-like behaviour of the FSL rats might be caused by other underlying 
mechanisms that do not involve changes in central mRNA levels of these 
cytokines. It is questionable whether the Flinders depression model is a suitable 
tool to study cytokine-related mechanisms in depression, but our findings in 
Paper I and II indicate that it might be a useful model in the study of the 
serotonin system and the glial marker S100B in depression. Regarding the 
reduced expression of Il1b, Il18, Mmp9, and Timp1 observed in some brain 
regions, future studies are needed to explore the relevance of these findings for 
the Flinders depression model. 
Effect of LPS on central gene expression (Paper I) 
The behavioural data from Paper I, confirming sickness behaviour after LPS 
administration, are further confirmed by elevated mRNA levels of several 
immune mediators in response to LPS. These include IL-1beta and TNF, which 
are the main pro-inflammatory cytokines involved in sickness behaviour. 
Considering that we found no differences in mRNA levels in response to LPS 
between FSL and FRL rats, it is unlikely that differences in sensitivity to acute 
inflammatory mechanisms are involved in the behavioural differences between 
the rat lines. Also, we found no effect of LPS on the expression of S100B, leading 
to the conclusion that this substance is not part of the sickness behaviour in this 
model. This is in contrast to a finding regarding S100B transgenic female mice 
displaying depressive-like behaviour in the forced swim test 227. 
LPS caused significant upregulation of 5-HT2A receptor mRNA levels in the 
striatum of the FSL/FRL rats, indicating a possible sensitivity of this receptor to 
immune changes in this brain region. Apart from their function in e.g., 
monoaminergic signaling 228, 5-HT2A receptors are proposed to play a role in 
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inflammation 229 although whether this role is pro- or anti-inflammatory is 
unclear 230–232. It is suggested that  5-HT2A receptor agonists mediate anti-
inflammatory effects through disruption of TNF receptor downstream signaling, 
thereby inhibiting NF-κB nuclear translocation and transcription of pro-
inflammatory markers such as IL-6 and TNF itself 229,231. These 5-HT2A receptor 
agonists, also known as psychedelics, have—due to their anti-inflammatory 
effects—been proposed as treatment for several inflammatory disorders, and are 
viewed as promising new treatment options for a variety of disorders 233, 
including anxiety and depression, constituting a renaissance more than half a 
century after their initial use as treatment for these disorders 234,235. It is 
hypothesized that 5-HT2A agonists exert their immediate antidepressant effects 
through a resetting of resting state functional connectivity to healthy networks, 
and then produce long-lasting effects by reducing neuroinflammation 233. Why 
serotonin acting at 5-HT2A receptors is primarily pro-inflammatory, but other 5-
HT2A receptor agonists anti-inflammatory, is yet to be clarified. It is hypothesized 
that this discrepancy among the effects of substances which all activate the 
receptor might be due to functional selectivity, that is, serotonin inducing a 
conformation of the receptor that activates pro-inflammatory signaling 
pathways, and other 5-HT2A receptor agonists stabilizing the same receptor in 
another conformation that recruits anti-inflammatory pathways 233. 
Effect of chronic SSRI treatment on central gene expression 
(Paper II) 
Our findings that antidepressant treatment with the SSRI escitalopram lowered 
mRNA levels of S100B and the 5-HT2A receptor in the amygdala and 
hypothalamus of FSL and FRL rats further confirm the validity of this animal 
model in studying the action of antidepressants. 
Genetic studies of the 5-HT2A receptor have shown significant associations 
between variants in the gene encoding this receptor and treatment response to 
antidepressants 236,237. Interestingly, a down-regulation of 5-HT2A receptors has 
been reported following long-time treatment with antidepressants in humans 238–
240, suggesting that this mechanism might be central for their therapeutic effect. 
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Antidepressant treatment has been shown to reduce serum levels of S100B in 
patients with depression 241, and baseline levels of S100B have been associated 
with treatment response to antidepressants 196,242. However, studies have also 
shown no effect of antidepressant treatment on elevated S100B levels despite 
clinical improvement 91,196,243. 
S100B has also been implicated in serotonergic neurotransmission; S100B 
overexpressing mice showed a significant loss of serotonergic terminals in the 
hippocampus 48, and S100B secretion in turn has been shown to be induced by 
binding of serotonin (5-HT1A) receptor agonists and cytokines 244. Considering 
that FSL rats showed aberrant mRNA levels of both S100B and the 5-HT2A 
receptor at baseline, and that escitalopram treatment altered their levels in the 
same brain regions, one could speculate that S100B might, in part, be involved 
in 5-HT2A receptor function and that these two proteins constitute a common 
target for antidepressants. Further studies are warranted to explore the role of 
these two proteins in depression, and considering our findings in Paper I and 
II, the Flinders rat may be a suitable model in this regard. 
Our findings that escitalopram treatment had no effect on central cytokine levels 
in FSL rats is in contrast with the notion that antidepressants decrease 
inflammation; studies in patients with MDD have reported that antidepressants 
decreased peripheral levels of pro-inflammatory cytokines 245, and an 
experimental study showed that antidepressant treatment reduced up-regulation 
of cytokines in response to LPS in the brain and periphery of rats 246. However, 
the latter study investigated the effect of antidepressants on an acute 
inflammatory response, while our study addressed the effect on basal levels in 
the rat depression model. Alboni et al. also reported no changes in the 
expression levels of IL1b or Tnf in the rat hypothalamus after chronic treatment 
with either an SSRI or a tricyclic antidepressant 247, but a significant decrease in 
Il6 mRNA after both types of antidepressants. These differences in gene 
expression might be attributable to using a different strain of rats, as well as a 
different SSRI (fluoxetine). Another possible factor influencing results may be 
the dosages of antidepressants used. Our results suggest that the documented 
antidepressant effect of escitalopram on the depressive-like behaviour in this 
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Flinders rat model might be caused by other underlying mechanisms that do not 
involve changes in mRNA levels of these cytokines. 
HUMAN GENETIC ASSOCIATION STUDIES (PAPER III & IV) 
Variants in NFKBIL1 and autistic-like traits (Paper III) 
Since it has been difficult to replicate common genetic variant findings in case-
control studies of mental disorders, investigations of endophenotypes may be 
another strategy to gain insight into the influences of common genetic variations 
in e.g. autism. In Paper III, we investigated common SNPs in immune-related 
genes in relation to ALTs and also used a dichotomous cutoff that has been used 
as a validated proxy for a clinical diagnosis of autism 153,248. 
We found associations between ALTs and two polymorphisms in NFKBIL1, a 
gene that is located in the HLA region. The HLA region encodes several 
molecules that play key roles in the immune system, and has been implicated in 
autism before 165,249,250. A nominal association between rs2230365 and autism 
has been reported in an earlier genome-wide autism case-control study by the 
Autism Genetics Group 250, and our finding that rs2230365 was associated with 
a clinical proxy for autism replicates this. 
Moreover, the same rs2230365 SNP was associated with the ALT module 
language impairment. Although atypical language development is no longer part 
of the DSM-5 diagnostic criteria for ASD (see supplementary table D), language 
anomalies or impairments are a characteristic of autism 148. Language 
impairment has been associated with HLA alleles previously 251, and the HLA 
region has been implicated in dyslexia 252, suggesting a role of HLA loci in 
language disorders. 
Our data suggest that variants in NFKBIL1 may possibly contribute to ASD risk 
and some autistic traits. Only a modest genetic overlap has been reported with 
respect to social and nonsocial ALTs 152, and different genetic influences may be 
of importance in various autistic endophenotypes. We therefore conclude that 
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it might be advantageous to consider autistic traits separately in order to 
elucidate how neuropsychiatric symptoms develop. One could speculate that 
SNPs in NFKBIL1 might lead to alterations in immune function, possibly 
causing developmental dysfunctions in conjunction with other risk factors. 
Further studies of this gene are therefore warranted in order to elucidate its role 
in brain development.  Moreover, the possible functional implications of the 
studied polymorphisms should be investigated. 
It should be noted that candidate gene studies have been subject to criticism; 
recent studies investigating the effect of genes that have been previously 
implicated in disorder phenotype, found that historical candidate gene literature 
was essentially uninformative for the genetic basis of several mental disorders, 
including schizophrenia 253, and depression 75. However, autism has been shown 
to have a much higher genetic component than depression 67, while epigenetic 
alterations possibly play a more important role in the mechanisms leading to 
depression 254. Also, a point of criticism regarding candidate gene studies is the 
small sample sizes frequently employed; many candidate gene association studies 
have likely been severely underpowered, as e.g. discussed by Border et al. 75. This 
is unlikely regarding our study, considering the sample size in Paper III (n= 
12,319). It should be noted that two more recent GWAS have not shown any 
association with polymorphisms in NFKBIL1 and autism 161,162, and, although 
corrected for multiple testing, our results should be interpreted with caution. 
Variants in IL1B and volume of brain regions (Paper IV) 
The pro-inflammatory cytokine IL-1beta is produced by activated immune cells 
and plays a key role in the onset of inflammatory processes and the acute phase 
response. However, it has also been implicated in mood disorders in a number 
of studies, for a review see Maes et al. 255. IL-1beta has been shown to be of 
relevance for embryonic development of the CNS, where it promotes 
proliferation and production of cytokines and trophic factors 256, together with 
neurodegeneration 257. Experimental studies also point to a role of IL-1beta in 
axonal plasticity after spinal cord injury (Boato et al., 2013), as well as in 
hippocampal synaptic plasticity (Erion et al., 2014). Patients with bipolar 
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disorder have higher peripheral IL-1beta levels compared with controls 125, a 
trend that has also been observed in depression 255. Also, levels of IL-1beta were 
elevated in the CSF of bipolar patients compared with controls – an observation 
that was even more pronounced depending on the manifestation of 
manic/hypomanic episodes during the year prior to sampling 129. 
Our results do not support a role of the studied IL1B gene variants in bipolar 
disorder, as we found no differences in genotype distribution between patients 
and controls. This is in contrast with a study by Papiol et al. associating IL1B 
polymorphisms with bipolar disorder 123. 
Our analyses revealed two IL1B polymorphisms (i.e., rs16944 and rs1143627) 
to be associated with volumes of the putamen of the left hemisphere in patients 
and controls. Alterations in grey matter brain volume have previously been 
associated with polymorphisms in cytokine-encoding genes 258,259, and with 
peripheral cytokine levels 260. It has been suggested that the size/volume of brain 
regions is associated with intrinsic brain activity and cognitive functions 261, and 
with regard to the findings concerning rs16944 and rs1143627 in this thesis, 
one might speculate that IL-1beta is of relevance for mental functions. 
Our findings contradict yet another study by Papiol et al.; while they report 
associations between the T allele at rs16944 with lower grey matter volumes 262, 
we find this allele to be associated with increased volume of all investigated areas, 
although only the association with the left putamen survived correction for 
multiple testing. However, there are several possible reasons for why our results 
differ from those of Papiol et al.; first of all, their sample size (n=20) was very 
small; second, their results were not corrected for multiple testing; and third, 
they investigated grey matter in the PFC, an area that was not investigated in 
our study. Nevertheless, associations between this allele and frontal grey matter 
deficits have also been reported in schizophrenic patients but not in healthy 
controls 263, with no difference in genotype distribution between patients and 
controls. Also, a study in patients with depression found no association with this 
genetic polymorphism 264, suggesting that this variant in the gene coding for IL-
1beta might not lead to a pathogenic phenotype per se. However, the 
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associations seen with alterations in volume of different brain regions indicate 
that this polymorphism may have an impact on neurodevelopment or other 
processes affecting brain region volume. 
Both rs16944 and rs1143627, two polymorphisms that are in strong linkage 
with each other, lie in the promoter region of the IL1B gene and may affect 
binding of transcription factors. In vitro studies have investigated the functional 
implications of these variants; a haplotypic combination of rs16944 and 
rs1143627 has been associated with increased binding of transcription factors 
to the IL1B promoter in vitro 265, and the C allele at rs1143627 has been found 
to inhibit protein complex formation at this site, indicating that some 
transcription factors may be unable to bind and form the transcription initiation 
complex 266. However, the latter study found no differences in binding activity 
for the T allele at rs16944. 
The T allele at rs16944 has also been associated with later onset of depression267 
and with lower severity of depressive symptoms, as well as with faster and more 
pronounced treatment response 264,268 to antidepressant treatment. Together, 
these data point to mechanisms involving this IL1B polymorphism which may 
influence disease onset and treatment response in individuals who are perhaps 
already vulnerable to depression, but do not cause the disorder or affect its 
severity per se. 
Our study adds to the existing literature regarding associations between genetic 
variants in immune markers and altered brain volume 258,259, further supporting 
a role of immune mediators, especially IL-1beta, in neurodevelopment.  
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CONCLUDING REMARKS 
The psychiatric disorders discussed in this thesis—depression, bipolar disorder, 
and autism—are highly heterogenous disorders, both with regard to their 
phenotypical manifestations, and to the genetic factors that may contribute to 
their etiology and pathophysiology. Nevertheless, a multitude of studies point to 
a dysfunctional immune system as a possible common denominator for mental 
disorders; aberrant cytokine levels have been reported both in the periphery and 
CNS of patients suffering from these disorders, and immune-related genes and 
neuro-immune pathways have been implicated in several psychiatric conditions. 
However, the underlying mechanisms of immune-related factors in mental 
disorders are not yet fully understood. 
This thesis investigates the role of the immune system in the abovementioned 
psychiatric conditions, utilizing experimental, population-based, and clinical 
studies. 
In the experimental studies, we used the Flinders genetic rodent model of 
depression, showing differences between the affected animals and their controls 
in basal expression levels of various immune-related genes—including also a 
serotonergic receptor that has been linked to the immune system—in several 
brain regions relevant for depression, thereby increasing our knowledge of this 
animal model. We believe that the results regarding the glial-specific protein 
S100B and the serotonergic receptor 5-HT2A may not only be useful for future 
experiments using Flinders rats, but also in further investigations of the role of 
these proteins in affective disorders.  
As our results regarding immune markers are inconsistent with findings in 
depressed humans, this model requires further examination to clarify its value 
in the study of the association between cytokines and depression. Furthermore, 
we found no dissimilarities between the two rat lines after treatment with an 
immune stimulant or with the antidepressant escitalopram, suggesting no basic 
differences in immune response or sensitivity to antidepressant treatment. 
However, the observation that antidepressant treatment reduced the central 
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expression of S100B is interesting and valuable since this protein has been 
linked to the serotonergic system in previous animal and human studies. 
To replicate findings in genetic association studies is often difficult and renders 
a large number of investigations inconclusive. In this thesis, we replicated a 
previous finding showing an association between a polymorphism in NFKBIL1 
and autism. Even though there is no consensus in the literature about this 
genetic variant in autism yet, our finding further reinforces the impact of the 
immune system on neuropsychiatric disorders. 
Our finding that the same variant in the NFKBIL1 gene is specifically associated 
with language impairment, as opposed to social interactions and 
restrictive/repetitive behaviour, strengthens the notion that different 
endophenotypes of complex psychiatric conditions have distinct underlying 
causes. Our data, together with studies showing that maternal infections during 
pregnancy increase the risk of an autism diagnosis in the offspring, point to the 
impact of the immune system during brain development and may lead to a better 
understanding of the consequences of infections during pregnancy. 
In our study of the impact of variants in the cytokine IL-1beta gene (IL1B) on 
brain regional volumes, we found no differences in the studied gene between 
patients diagnosed with bipolar disorder and controls. Although the literature 
on this remains unclear, our results suggest that the studied polymorphisms in 
IL1B may not be directly associated with bipolar disorder. 
Nonetheless, analyses of the IL1B variants and brain volume revealed that this 
gene is associated with the volume of all studied brain regions, as well as total 
grey matter volume. Particularly, the association between two polymorphisms 
and volume of the left putamen survived correction for multiple testing. Again, 
while previous results are inconsistent, our data imply the influence of the 
immune system on neurodevelopment. The underlying mechanisms for this 
association are not obvious yet; IL-beta may directly affect brain development or 
other systems of relevance. Nevertheless, IL-1beta has previously been associated 
with both neural plasticity and psychiatric disorders, and our results are in line 
with the hypothesis that the influence of the immune system on 
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neurodevelopment may be associated with the origin and pathogenesis of 
psychiatric symptoms. 
The work presented in this thesis confirms the importance of the immune 
system for mental functions and possibly for brain development. There is an 
intricate balance of immune-regulated processes in the CNS, and one cannot 
simply view immune activation in the brain as beneficial or detrimental. 
Additionally, psychiatric conditions are highly heterogeneous and different 
causes and mechanisms may underlie the various symptoms; perhaps some of 
these symptoms may be treated by modulating the immune system. Exploration 
of the interactions between brain, behaviour, and immunity is central to our 
understanding of the pathology of psychiatric disorders, and might lead to the 
development of new treatment strategies for at least a subgroup of the afflicted. 
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APPENDIX 
DEFINITIONS 
Molecular genetics 
The instruction manual for the creation of all living organisms is written in their 
genes in the form of DNA, using only four letters: adenine (A), guanine (G), 
cytosine (C) and thymine (T). By binding to a pentose sugar (2’-deoxyribose), 
which forms the backbone of the structure, these bases (then called nucleotides) 
form hydrogen bonds with each other (A to T and C to G) and form a double 
helix, which is tightly wrapped and stored as chromosomes. The human genome 
is made up of 23 chromosome pairs (a total of 46 chromosomes), with one copy 
from the mother, and one from the father. Thus, each gene is present in two 
copies, and they can differ to some extent due to e.g. mutations causing genetic 
variability and subsequent phenotypic variation (see below). Only approximately 
1,5% of the human genome consists of protein-coding sequences (called exons) 
(Figure 3). The other non-coding sequences are made up of e.g. introns, regulatory 
sequences such as promoters and enhancers, repetitive sequences, or encode 
functional non-coding RNA molecules. It is still not known why there is so much 
non-coding DNA, but many of these sequences have been found to be involved 
in the regulation of gene expression. 
The synthesis of proteins involves two steps: transcription and translation. First, 
the specific part of the chromosome containing the desired genes is unwrapped 
and transcribed into ribonucleic acid (RNA). These contain both exons and 
introns, and the latter have to be removed in a process called splicing, leading 
to messenger RNA (mRNA). mRNA is then transported from the nucleus into the 
cytoplasm of the cell, where it serves as a template for the translation into 
proteins. The amino acid sequence of a protein is determined by the genetic 
code, which consists of three letter “words” called codons. Each codon is formed 
from a sequence of three nucleotides, e.g CGG GAC AGC, which codes for 
arginine (Arg), aspartic acid (Asp) and serine (Ser), respectively. 
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Figure 3.  A chromosome pair with tightly packed DNA. Upon transcription, the DNA is uncoiled, revealing 
the double helix structure and different regions of a gene: the promoter, which initiates transcription, the protein-
coding exons, and introns. After transcription, the introns are spliced out and the mRNA is transported from 
the nucleus into the cytoplasm, where it is translated into protein. Each gene is present in two copies (one from 
the mother and one from the father), and differences at one base pair are called a single nucleotide 
polymorphism (SNP), shown in red. Adapted from https://commons.wikimedia.org/wiki/File:Chromosom-
DNA-Gen.png 
Since three letter words made up of four different letters give rise to 43=64 
different combinations, with only 20 different amino acids being coded for, plus 
three stop codons, more than one codon codes for an amino acid. If a mutation 
occurs at a site in the genetic code (this site is called an allele, while the 
combination of alleles is the genotype), it can either change the encoded amino 
acid (non-synonymous), introduce a stop codon (nonsense), or have no effect on 
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the amino acid and be silent (synonymous), or simply occur in the noncoding 
regions. There it may influence promoter activity and gene expression, mRNA 
conformation and stability, or subcellular localization of mRNAs and/or 
proteins and hence may produce a different phenotype or even a disease. 
Genotype, phenotype, and epigenetics 
The genotype is the full genetic hereditary information (i.e. DNA sequence) of a 
cell, organism or individual. The phenotype is all of its observable characteristics, 
such as morphology, development and behaviour, and is influenced both by 
genotype and environment. One way how the environment can affect the 
phenotype is through epigenetic mechanisms. Epigenetics is the study of heritable 
changes in gene expression without a change in DNA sequence, i.e. changing 
the phenotype without changing the genotype. Epigenetic modifications such as 
DNA methylation or histone modification change the accessibility of DNA and 
chromatin structure, thereby regulating patterns of gene expression. To give an 
analogy; if the DNA is all the books in a library, epigenetic mechanisms are the 
librarians, deciding which books to lock away and which ones to display. Every 
single cell in our body contains, or used to contain, that entire library, and 
epigenetic mechanisms, together with a plethora of signals, causes different 
genes to be read and expressed, leading to e.g., different cell types and tissues. 
Another term often used in psychiatric genetics is endophenotype, which can be 
defined as a heritable, simple component of a disease phenotype. For a 
behavioural symptom to be called an endophenotype it must have a clear genetic 
connection and segregate with illness within the population and, to a higher 
extent, within families of affected individuals, and it must be measurable and 
specific to the illness of interest. Investigations of endophenotypes are a strategy 
to gain insight into the genetic components underlying the phenotype 
heterogeneity of complex psychiatric disorders. 
Genetic variation 
All humans are approximately 99,9% similar in their genetic code. It is the 
remaining 0,1% variation, together with environmental factors, that makes each 
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of us unique. These variations all stem from mutations such as base pair 
substitutions, deletions, insertions, or copy number variations. If a genetic locus 
displays different forms of alleles in more than 1% of the population, it is called 
a polymorphism, and a single nucleotide polymorphism (SNP) is a change in one 
single base-pair. 
The first method to sequence DNA was invented in the 1970s and called Sanger 
sequencing, after its founder Frederick Sanger. It was used to sequence the first 
gene 269 and more than twenty years later, with an immense workload and costs, 
the first genome 270. With the development of next generation sequencing, or 
massive parallel sequencing, it became possible to sequence the whole genome 
quickly and at a substantially lower cost. Nowadays, this method is used to 
sequence large populations in order to search for e.g. the genetic basis of 
different phenotypes or diseases. 
Heritability 
Heritability measures to what extent variation in a phenotypic trait in a 
population is due to genetic variation between individuals in that population. 
That does not mean that this fraction of a phenotype is genetic. For example, if 
everyone in a population has the same allele for a trait and shows little variation 
on that trait, then the heritability for that trait is zero. One example is the 
number of fingers: 100% due to genetic factors, but 0% heritability (because 
that trait has no genetic variation). In other words, heritability is the proportion 
of the variation in a given trait within a population that is not explained by 
environment or random chance. It is estimated by comparing individual 
phenotypic variation among related individuals in a population, and one of the 
most commonly used heritability estimation methods is twin studies, in which 
the impact of genetic and environmental factors is identified by comparing the 
concordance between monozygotic (MZ) and dizygotic (DZ) twin pairs. A high 
concordance means that both subjects in a twin pair will likely have the same 
phenotype/disease. If the concordance rate for monozygotic twins is twice as 
high as for dizygotic twins, it is interpreted as a high heritability for the specific 
disease or trait. 
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Linkage disequilibrium 
Humans receive one set of chromosomes from their mother, and one from their 
father, and during meiosis (i.e. the creation of egg or sperm cells; DNA 
replication followed by two rounds of cell division, resulting in four haploid 
cells) homologous chromosomes exchange parts of their DNA in a process called 
genetic recombination. This makes it possible that offspring can have traits 
depending on genes that lie on the same chromosome from all four of their 
grandparents and leads to greater genetic diversity. Regions that are close 
together on the same chromosome are often inherited together, as the 
probability that a recombination occurs between to alleles increases with the 
distance between them. Linkage disequilibrium (LD) is the non-random 
association of alleles at different loci, i.e. loci are said to be in LD when they are 
inherited together more often (or seldom) than would be expected from random 
and independent recombination. If two loci are in complete LD, one can predict 
the outcome of the other. However, it is possible that one locus may predict the 
outcome of the other, but not the other way around. A haplotype is the specific 
combination of alleles on a chromosome that are inherited together from a 
single parent, but also a set of SNP alleles that tend to always occur together (i.e., 
that are statistically associated). LD-information is used by essentially all genetic 
studies to establish to what extent genetic variation may influence a complex 
trait or disease. 
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Structures and circuits of the brain 
The limbic system 
Various scientists have attempted to elucidate the neural systems that control 
human emotions and behaviour throughout the centuries, but there is still 
much to be found out regarding the neuroanatomy of emotion. In 1878, Paul 
Broca, a French physician best known for his research on the anatomical 
location of language and Broca´s area, coined the term limbic lobe, describing a 
collection of cortical areas that form a border (latin: limbus) around the brain 
stem. However, they were not yet associated with emotion but primarily thought 
to be involved in olfaction. Almost 50 years later the American neuroanatomist 
James Papez described a neural pathway in the brain as “the anatomical basis of 
emotion”, called the Papez circuit. This included the cingulate cortex, anterior 
thalamic nucleus, hypothalamic mammillary bodies, and hippocampus, with 
each area being connected to another by a major fiber tract (Figure 4A) 271. 
Figure 4. Schematic briefly summarizing neural systems proposed to process emotion, highlighting structures 
that are visible on the medial surface of the brain. Papez's (1937) original circuit (A) was expanded upon in 
the concept of the limbic system (B) to include a variety of subcortical and cortical territories. From Barger et 
al. 2014 271 http://journal.frontiersin.org/article/10.3389/fnhum.2014.00277/full. 
Papez believed that the cortex is an important part of the experience of 
emotions, and that this “emotional system” links the cortex with the 
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hypothalamus. These structures have been thought to be involved in emotion 
since then, with the American physiologist Paul MacLean reintroducing the 
term limbic system in the 1950s, expanding the emotion network to include 
several more areas (Figure 4B). However, some of the components central to the 
limbic system are no longer thought to be central to the expression of emotion 
(such as the hippocampus), and some structures involved in emotion have also 
been shown to be involved in other functions 272. 
Considering the diversity of emotions that we experience, it seems reasonable, 
however, that more than one system is involved. Although the term limbic system 
is still frequently used, and its components thought to be involved in emotion, 
motivation, learning and memory, the current consensus is that it is certain 
brain structures that are particularly important for the experience and 
expression of emotions. 
The basal ganglia 
The basal ganglia are a set of structures including the 
- striatum: ventral striatum (nucleus accumbens and the olfactory tubercle) 
dorsal striatum (putamen and caudate nucleus) 
- globus pallidus in the cerebrum 
- substantia nigra in the midbrain 
- subthalamic nucleus in the diencephalon 
- ventral pallidum 
These structures lie deep within each of the cerebral hemispheres in the 
cerebrum, over and to the sides of the limbic system, with which they interact, 
and are tightly connected to the cerebral cortex, thalamus, and brainstem, as 
well as several other brain regions. Their function can be summarized as being 
“principally involved in the selection and implementation of purposeful actions 
in response to external and internal cues”, as they are an important part of the 
brain systems that control motor movement (including initiation and 
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termination of movements), but have also been implicated in other circuits 
involving emotion, memory, learning, language, decision making, cognitive 
function and reward 273. 
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MATERIAL AND METHODS 
Ethics in research 
All studies in this thesis were approved by the respective ethics committees. The 
animal studies presented in Paper I and II were approved by the Animal Ethics 
committee for Animal Experiments in Gothenburg, Sweden, and by the Danish 
National Committee for Ethics in Animal Experimentation, respectively. In 
accordance with the “three R’s” (refine, reduce, replace), all efforts were made 
to minimize animal suffering and to reduce the number of animals used to what 
was deemed necessary for the objectives of each experiment. The human genetic 
association studies were approved by the Karolinska Institutet Ethical Review 
Board (Paper III) and by the Stockholm Regional Ethical Review Board (Paper 
IV). Informed consent was given by all participants. 
Animal models in psychiatric research 
As it is difficult to study endogenous proteins and their role in e.g. mood 
disorders in the human brain, animal studies prove to be of importance for 
exploring these questions. However, since psychiatric diagnoses are based on the 
verbal description of symptoms reported by the patient and/or relatives, it is 
problematic to model these conditions in animals. Some symptoms that may be 
central to some afflicted by mood disorders, such as guilt and worthlessness are 
difficult to model in animals. Therefore, attempts have been made to develop 
animal models that focus on other symptoms, modelling more basal fear and 
stress responses. This can be done either based on the animal itself, e.g. a genetic 
model, or on the study of a behaviour that can be altered by e.g. pharmacological 
intervention which shows similar effects as in humans. 
The quality of an animal model can be measured by three criteria: face, 
predictive and construct validity. Face validity means that something similar to 
the studied phenomenon is also present in humans (i.e. symptoms). The second 
criteria, predictive validity, concerns itself with effects of treatments, i.e. a 
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compound with a known effect in humans has a similar effect in the animal 
model, while a compound without any effect in humans also shows no response 
in the model. Construct validity, the third criteria, describes how similar the 
underlying mechanisms between the condition in humans and the animal 
model are. Since both the etiology and the pathophysiology of mood disorders 
are far from understood, this is perhaps the most difficult to achieve and can 
only be speculatively discussed in animal models. 
In this thesis we combined two animal models used in depression research; the 
Flinders sensitive line (FSL) rat, a genetic animal model of depression 274, and the 
forced swim test, in which animals can be tested for sickness or depressive-like 
behaviour and the effect of antidepressant treatment 275,276 The FSL rat, 
originally bred to develop a resistance to irreversible anticholinesterase agents, 
instead turned out to be more sensitive to these agents, which has also been 
noted in depressed patients 277. FSL animals also share several behavioural 
characteristics with depressed humans, including reduced appetite, reduced 
psychomotor function, sleep disturbances, and, interestingly, immune 
abnormalities such as reduced cytotoxic T lymphocyte activity 278, thus showing 
a modest degree of face validity. FSL rats have higher immobility scores in the 
forced swim test than their controls 279, which can be reversed by different 
antidepressants, including SSRIs 274, indicating good predictive validity. Also, 
neurochemical abnormalities have been observed in Flinders rats, including 
imbalances of the serotonergic, cholinergic, and immune systems 274, suggesting 
construct validity. 
The forced swim test is a behavioural test that is widely used to evaluate 
antidepressant activity in rats and mice. The animals are placed in an inescapable 
cylinder filled with water, and after escape-oriented movements (“climbing”) 
they either swim or develop an immobile posture (“immobility”). If the test is 
repeated 24 hours later, they usually resume this posture quickly. This 
immobility is believed to reflect either giving up escape-directed behaviour (i.e. 
behavioural despair) 276 or a diminished ability to cope with stressful stimuli 280. 
While the forced swim test shows relatively little face or construct validity, its 
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major advantage is a very high predictive validity, as antidepressant treatment 
significantly decrease the time spent immobile in the tested animals 274,281. 
However, it is important to emphasize that the behaviour of rodents differs 
greatly from that of humans, and that human depression and depressive-like 
behaviour in an animal model are two vastly different things. The fact that 
antidepressant treatment, which suppresses symptoms of depression in humans, 
also reduces depressive-like behaviour in an animal model, neither means that 
this behaviour is directly comparable with depression, nor that every other 
compound with antidepressant effects in humans will inhibit the behaviour in 
that animal model. Therefore, data from animal models of behaviour should 
always be interpreted with great caution, although they may nonetheless provide 
important insights into the underlying mechanisms of e.g. psychiatric disorders. 
Human genetic association studies 
Genetic association studies analyze the co-occurrence of a trait or phenotype 
with one or more genotypes, i.e. single-locus allele frequencies or haplotype 
frequencies are compared between groups (e.g., case-control) or for quantitative 
traits (e.g., continuous measures). Association analyses have been used in 
candidate gene studies since the 1990’s, and with the introduction of the 
genome wide SNP-genotyping arrays (see chapter “Genetic variation” above), it 
became possible to perform GWAS. The advantages with GWAS are 
undoubtedly abundant, enabling the examination of possible associations 
between a phenotype and thousands of variants across the genome. However, 
candidate gene studies allow for a more focused, hypothesis driven investigation 
of endogenous molecules. Considering the intricate and complex relationship 
between the immune system and brain functions, cause and effect are not always 
evident, i.e., is dysregulation of the immune system causing a phenotype, or is it 
a result thereof. The advantage of the candidate gene approach is that possible 
associations between the genetic code and a phenotype can be established. 
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Magnetic resonance imaging 
MRI is an imaging technique used in radiology to form pictures of the anatomy 
and the physiological processes of the body in both health and disease. It is a 
widely used technique for medical diagnosis and research applications, and the 
method of choice for many conditions of the CNS due to the contrast between 
white and grey matter in the image. In contrast to computer tomography or 
positron emission tomography, MRI does not involve the use of radiation; 
however, it might create discomfort, as the scans usually take longer and are 
louder, and require the tested subject to enter a narrow, confining tube. 
MRI is based on the magnetic properties of atomic nuclei, and uses the nuclear 
spins of protons in hydrogen nuclei that are contained in a tissue when placed 
in a magnet field. For that, it uses strong magnetic fields, magnetic field 
gradients, and radio waves to generate images of the organs in the body. Most 
MRI examinations target hydrogen in water molecules. As the brain contains 
approximately 80% water, an image can be constructed with MRI. For that, the 
nucleus will be excited with electromagnetic energy and taken from a low-energy 
state to a high-energy state. When the nucleus falls back into the low-energy state, 
magnetic oscillations from the nucleus induce current in a receiver coil, forming 
the basis of the MRI signal. 
After excitation, each tissue returns to its equilibrium state during a relaxation 
process. Two types of relaxation can be determined: T1 and T2. To create a T1-
weighted image, magnetization is allowed to recover before measuring the MR 
signal, and this image weighting is useful for obtaining morphological 
information, e.g., the cerebral cortex or fatty tissue. To create a T2-weighted 
image, magnetization is allowed to decay before measuring the MR signal, and 
this image weighting is useful for detecting e.g., edema and inflammation. In 
our study (Paper IV), the MRI images that were analysed were T1-weighted. 
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SUPPLEMENTARY MATERIAL 
Supplementary Table A. DSM-5 Criteria for Major Depressive Disorder 
______________________________________________________________ 
A. Five (or more) of the following symptoms have been present during the 
same 2-week period and represent a change from previous functioning; at 
least one of the symptoms is either (1) depressed mood or (2) loss of 
interest or pleasure: 
1. Depressed mood most of the day 
2. Markedly diminished interest or pleasure in all, or almost all, 
activities most of the day 
3. Significant weight loss when not dieting or weight gain, or 
decrease or increase in appetite 
4. Insomnia or hypersomnia 
5. Psychomotor agitation or retardation 
6. Fatigue or loss of energy 
7. Feelings of worthlessness or excessive or inappropriate guilt 
8. Diminished ability to think or concentrate, or indecisiveness 
9. Recurrent thoughts of death (not just fear of dying), recurrent 
suicidal ideation without a specific plan, or a suicide attempt or a 
specific plan for committing suicide 
B. The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning. 
C.  The episode is not attributable to the physiological effects of a substance 
or to another medical condition. 
D. The occurrence of the major depressive episode is not better explained by 
schizoaffective disorder, schizophrenia, schizophreniform disorder, 
delusional disorder, or 
other specified and unspecified schizophrenia spectrum and other 
psychotic disorders. 
E.          There has never been a manic episode or a hypomanic episode. 
_________________________________________________________________ 
DSM-5=Diagnostic and Statistical Manual of Mental Disorders 5th edition 
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Supplementary Table B. DSM-5 Criteria for Bipolar I and II Disorder 
______________________________________________________________ 
For a diagnosis of bipolar I disorder, it is necessary to meet the following criteria 
for a manic episode. The manic episode may have been preceded by and may be 
followed by hypomanic or major depressive episodes. 
 
For a diagnosis of bipolar II disorder, it is necessary to meet the following criteria 
for a current or past hypomanic episode and the following criteria for a current or 
past major depressive episode. 
 
Manic Episode 
A.  A distinct period of abnormally and persistently elevated, expansive, or 
irritable mood and abnormally and persistently increased goal-directed 
activity or energy, lasting at least 1 week and present most of the day, 
nearly every day (or any duration if hospitalization is necessary). 
B.  During the period of mood disturbance and increased energy or activity, 
three (or more) of the following symptoms (four if the mood is only 
irritable) are present to a significant degree and represent a noticeable 
change from usual behavior: 
1. Inflated self-esteem or grandiosity. 
2. Decreased need for sleep (e.g., feels rested after only 3 hours of sleep). 
3. More talkative than usual or pressure to keep talking. 
4. Flight of ideas or subjective experience that thoughts are racing. 
5. Distractibility (i.e., attention too easily drawn to unimportant or 
irrelevant external 
stimuli), as reported or observed. 
6. Increase in goal-directed activity (either socially, at work or school, or 
sexually) or psychomotor agitation (i.e., purposeless non-goal-directed 
activity). 
7. Excessive involvement in activities that have a high potential for 
painful consequences (e.g., engaging in unrestrained buying sprees, sexual 
indiscretions, or foolish business investments). 
C.  The mood disturbance is sufficiently severe to cause marked impairment 
in social or occupational functioning or to necessitate hospitalization to 
prevent harm to self or others, or there are psychotic features. 
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D.  The episode is not attributable to the physiological effects of a substance 
(e.g., a drug of abuse, a medication, other treatment) or to another 
medical condition. 
 
Note: A full manic episode that emerges during antidepressant treatment (e.g., 
medication, electroconvulsive therapy) but persists at a fully syndromal level 
beyond the physiological effect of that treatment is sufficient evidence for a manic 
episode and, therefore, a bipolar I diagnosis. 
Note: Criteria A–D constitute a manic episode. At least one lifetime manic 
episode is required for the diagnosis of bipolar I disorder. 
 
Hypomanic Episode 
A. to D. see Manic Episode 
E. The episode is not severe enough to cause marked impairment in social or 
occupational functioning or to necessitate hospitalization. If there are 
psychotic features, the episode is, by definition, manic. 
F. The episode is not attributable to the physiological effects of a substance 
(e.g., a drug 
of abuse, a medication, other treatment). 
Note: A full hypomanic episode that emerges during antidepressant 
treatment (e.g., medication, 
electroconvulsive therapy) but persists at a fully syndromal level beyond 
the physiological effect of that treatment is sufficient evidence for a 
hypomanic episode diagnosis. However, caution is indicated so that one 
or two symptoms (particularly increased irritability, edginess, or agitation 
following antidepressant use) are not taken as sufficient for diagnosis of a 
hypomanic episode, nor necessarily indicative of a bi- polar diathesis. 
Note: Criteria A–F constitute a hypomanic episode. Hypomanic episodes are 
common in bipolar I disorder but are not required for the diagnosis of bipolar I 
disorder. 
_________________________________________________________________ 
DSM-5=Diagnostic and Statistical Manual of Mental Disorders 5th edition  
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Supplementary Table C. DSM-IV Criteria for Autistic Disorder 
______________________________________________________________ 
 A. A total of six (or more) items from (1), (2), and (3), with at least two from (1), 
and one each from (2) and (3). 
 
(1) Qualitative impairment in social interaction, as manifested by at least two of 
the following: 
(a) Marked impairments in the use of multiple nonverbal 
behaviors such as eye-to-eye gaze, facial expression, body posture, 
and gestures to regulate social interaction 
(b) Failure to develop peer relationships appropriate to 
developmental level 
(c) A lack of spontaneous seeking to share enjoyment, interests, 
or achievements with other people 
(d) Lack of social or emotional reciprocity 
(2) Qualitative impairments in communication as manifested by at least one of the 
following: 
(a) Delay in, or total lack of, the development of spoken language 
(not accompanied by an attempt to compensate through 
alternative modes of communication such as gesture or mime)  
(b) In individuals with adequate speech, marked impairment in 
the ability to initiate or sustain a conversation with others 
(c) Stereotyped and repetitive use of language or idiosyncratic 
language 
(d) Lack of varied, spontaneous make-believe play or social 
imitative play appropriate to developmental level 
(3) Restricted, repetitive and stereotyped patterns of behavior, interests and 
activities, as manifested by at least two of the following: 
(a) Encompassing preoccupation with one or more stereotyped 
and restricted patterns of interest that is abnormal either in 
intensity or focus 
(b) Apparently inflexible adherence to specific, nonfunctional 
routines or rituals 
(c) Stereotyped and repetitive motor mannerisms (e.g hand or 
finger flapping or twisting, or complex whole-body movements) 
(d) Persistent preoccupation with parts of objects 
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B. Delays or abnormal functioning in at least one of the following areas, with 
onset prior to age 3 years: 
(1) social interaction, (2) language as used in social communication, (3) symbolic 
or imaginative play 
C. The disturbance is not better accounted for by Rett's Disorder or Childhood 
Disintegrative Disorder 
________________________________________________________________ 
DSM-IV=Diagnostic and Statistical Manual of Mental Disorders 4th edition 
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Supplementary Table D. DSM-5 Criteria for Autism Spectrum Disorder 
______________________________________________________________ 
A.  Persistent deficits in social communication and social interaction across 
multiple contexts, as manifested by the following, currently or by history: 
1. Deficits in social-emotional reciprocity 
2. Deficits in nonverbal communicative behaviors used for social 
interaction  
3. Deficits in developing, maintaining, and understanding 
relationships 
B. Restricted, repetitive patterns of behavior, interests, or activities, as 
manifested by at least two of the following, currently or by history: 
1. Stereotyped or repetitive motor movements, use of objects, or 
speech 
2. Insistence on sameness, inflexible adherence to routines, or 
ritualized patterns or verbal nonverbal behavior 
3. Highly restricted, fixated interests that are abnormal in 
intensity or focus 
4. Hyper- or hyporeactivity to sensory input or unusual interests 
in sensory aspects of the environment 
C.  Symptoms must be present in the early developmental period (but may 
not become fully manifest until social demands exceed limited capacities, 
or may be masked by learned strategies in later life). 
D.  Symptoms cause clinically significant impairment in social, occupational, 
or other important areas of current functioning. 
E. These disturbances are not better explained by intellectual disability 
(intellectual developmental disorder) or global developmental delay. 
Intellectual disability and autism spectrum disorder frequently co-occur; 
to make comorbid diagnoses of autism spectrum disorder and intellectual 
disability, social communication should be below that expected for 
general developmental level. 
_________________________________________________________________ 
DSM-5=Diagnostic and Statistical Manual of Mental Disorders 5th edition 
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